Review Article

Mechanisms of Disease

Hepatitis B Virus Infection — Natural History and Clinical Consequences

Don Ganem, M.D., and Alfred M. Prince, M.D.

N Engl J Med 2004; 350:1118-1129March 11, 2004DOI: 10.1056/NEJMra031087

Article

In the past 10 years, remarkable strides have been made in the understanding of the natural history and pathogenesis of hepatitis B virus (HBV) infection. In this article we will review these advances, with particular reference to the implications for antiviral therapy.

History

Clinical and epidemiologic studies began to differentiate among various types of acute hepatitis in the decades after World War II. The groundbreaking studies of Krugman and colleagues in 1967 firmly established the existence of at least two types of hepatitis,1 one of which (then called serum hepatitis, and now called hepatitis B) was parenterally transmitted. Links to the virus responsible for this form of hepatitis were derived by serologic studies conducted independently by Prince and colleagues2-4 and by Blumberg and colleagues.5 Blumberg and colleagues, searching for serum protein polymorphisms linked to diseases, identified an antigen (termed Au) in serum from patients with leukemia, leprosy, and hepatitis, though the relationship of this antigen to hepatitis was initially unclear. By systematically studying patients with transfusion-associated hepatitis, Prince and coworkers independently identified an antigen, termed SH, that appeared in the blood of these patients during the incubation period of the disease, and further work established that Au and SH were identical.6,7 The antigen represented the hepatitis B surface antigen (HBsAg).8,9 These seminal studies made possible the serologic diagnosis of hepatitis B and opened up the field to rigorous epidemiologic and virologic investigation.

Virologic Features

Classification and Structure

Hepatitis B virus (HBV) is the prototype member of the Hepadnaviridae (hepatotropic DNA virus) family. Hepadnaviruses have a strong preference for infecting liver cells, but small amounts of hepadnaviral DNA can be found in kidney, pancreas, and mononuclear cells. However, infection at these sites is not linked to extrahepatic disease.10-13

HBV virions are double-shelled particles, 40 to 42 nm in diameter (Figure 1AFigure 1Structure of HBsAg-Associated Particles (Phosphotungstic Acid–Negative Stain).),14 with an outer lipoprotein envelope that contains three related envelope glycoproteins (or surface antigens).15 Within the envelope is the viral nucleocapsid, or core.16 The core contains the viral genome, a relaxed-circular, partially duplex DNA of 3.2 kb, and a polymerase that is responsible for the synthesis of viral DNA in infected cells.17 DNA sequencing of many isolates of HBV has confirmed the existence of multiple viral genotypes, each with a characteristic geographic distribution.18

In addition to virions, HBV-infected cells produce two distinct subviral lipoprotein particles: 20-nm spheres (Figure 1B) and filamentous forms of similar diameter (Figure 1A).16 These HBsAg particles contain only envelope glycoproteins and host-derived lipids and typically outnumber virions by 1000:1 to 10,000:1.

Viral Genes and Proteins

The HBV genome has only four long open reading frames. The preS–S (presurface–surface) region of the genome encodes the three viral surface antigens by differential initiation of translation at each of three in-frame initiation codons.15,16,19 The most abundant protein is the 24-kD S protein (which is known as HBsAg). Initiation at the most upstream start codon generates the M (or preS2) protein, the function of which is unknown. Initiation at the most upstream start codon yields the L (or preS1) protein, which is thought to play key roles in the binding of the virus to host-cell receptors20 and in the assembly of the virion and its release from the cell.21

The preC–C (precore–core) region encodes hepatitis B core antigen (HBcAg) and hepatitis B e antigen (HBeAg). These two proteins are also derived by alternative initiation of translation at two in-frame AUG codons.15,19 The internal AUG encodes the 21-kD C protein, the structural polypeptide of the viral capsid, whereas the upstream AUG directs production of the 24-kD preC protein. The preC region encodes a signal sequence, which directs the chain into the secretory pathway. As the chains traverse the Golgi complex, cleavage by cellular proteases generates HBeAg, a 16-kD fragment that is secreted into the blood.22 HBeAg plays no role in viral assembly, and its function is not clear. It is not required for viral replication; mutants bearing chain-terminating lesions within the preC region replicate well in culture and, in fact, arise frequently during natural infection.23

The P coding region is specific for the viral polymerase, a multifunctional enzyme involved in DNA synthesis and RNA encapsidation. The X open reading frame encodes the viral X protein (HBx), which modulates host-cell signal transduction and can directly and indirectly affect host and viral gene expression.19 X-protein activity is absolutely required for the in vivo replication and spread of the virus.24

Viral Replication Cycle

Figure 2Figure 2The Replication Cycle of HBV. shows the main features of the hepadnavirus replication cycle, the cardinal feature of which is the replication of the DNA genome by reverse transcription of an RNA intermediate.25 Incoming HBV virions are bound by cell-surface receptors, the identity of which remains unknown. After membrane fusion, cores are presented to the cytosol and transported to the nucleus. There, their DNA genomes are converted to a covalently closed circular (ccc) form,26 which serves as the transcriptional template for host RNA polymerase II. This enzyme generates a series of genomic and subgenomic transcripts.27

All viral RNA is transported to the cytoplasm, where its translation yields the viral envelope, core, and polymerase proteins, as well as the X and preC polypeptides. Next, nucleocapsids are assembled in the cytosol, and during this process a single molecule of genomic RNA is incorporated into the assembling viral core.28 Once the viral RNA is encapsidated, reverse transcription begins.28 The synthesis of the two viral DNA strands is sequential. The first DNA strand is made from the encapsidated RNA template; during or after the synthesis of this strand, the RNA template is degraded and the synthesis of the second DNA strand proceeds, with the use of the newly made first DNA strand as a template.25,27,29 Some cores bearing the mature genome are transported back to the nucleus, where their newly minted DNA genomes can be converted to cccDNA to maintain a stable intranuclear pool of transcriptional templates.26 Most cores, however, bud into regions of intracellular membranes bearing the viral envelope proteins. In so doing, they acquire lipoprotein envelopes containing the viral L, M, and S surface antigens and are then exported from the cell.

Pathogenesis of Hepatitis B

The HBV replication cycle is not directly cytotoxic to cells. This fact accords well with the observation that many HBV carriers are asymptomatic and have minimal liver injury, despite extensive and ongoing intrahepatic replication of the virus.30 It is now thought that host immune responses to viral antigens displayed on infected hepatocytes are the principal determinants of hepatocellular injury. This notion is consistent with the clinical observation that patients with immune defects who are infected with HBV often have mild acute liver injury but high rates of chronic carriage.31

The immune responses to HBV and their role in the pathogenesis of hepatitis B are incompletely understood. Correlative clinical studies show that in acute, self-limited hepatitis B, strong T-cell responses to many HBV antigens are readily demonstrable in the peripheral blood.32 These responses involve both major-histocompatibility-complex (MHC) class II–restricted, CD4+ helper T cells and MHC class I–restricted, CD8+ cytotoxic T lymphocytes. The antiviral cytotoxic T-lymphocyte response is directed against multiple epitopes within the HBV core, polymerase, and envelope proteins; strong helper T-cell responses to C and P proteins have also been demonstrated in acute infection. By contrast, in chronic carriers of HBV, such virus-specific T-cell responses are greatly attenuated, at least as assayed in cells from the peripheral blood. However, antibody responses are vigorous and sustained in both situations (although free antibodies against HBsAg [anti-HBs antibodies] are not detectable in carriers because of the excess of circulating HBsAg). This pattern strongly suggests that T-cell responses, especially the responses of cytotoxic T lymphocytes, play a central role in viral clearance. Figure 3Figure 3Cellular Immune Responses to HBV. summarizes the major types of cellular immune response to HBV.

The mechanisms by which cytotoxic T lymphocytes kill liver cells and cause viral clearance have been incisively investigated in transgenic mice that express viral antigens or contain replication-competent viral genomes in the liver.32,33 Because these mice harbor HBV genes in their germ-line DNA, they are largely tolerant to HBV proteins, and accordingly, clinically significant liver injury does not develop. However, if antiviral cytotoxic T lymphocytes of syngeneic animals are transferred into such mice, acute liver injury with many of the features of clinical hepatitis B develops.34 It is striking that, in this model, the number of hepatocytes killed by direct engagement between cytotoxic T lymphocytes and their targets is very small and clearly insufficient to account for most of the liver damage. This suggests that much of the injury is due to secondary antigen-nonspecific inflammatory responses that are set in motion by the response of the cytotoxic T lymphocytes. Presumably, much of the damage occurring in this context is due to cytotoxic by-products of the inflammatory response, such as tumor necrosis factor (TNF), free radicals, and proteases. Other immune-cell populations, notably natural killer T cells,35 probably also contribute to liver injury.

Recent experiments suggest that some of the inflammatory by-products, notably interferon-γ (IFN-γ) and TNF-α, can have antiviral effects that do not involve killing the target cells. When cytotoxic T lymphocytes are transferred to mice that bear replicating HBV, viral DNA and RNA throughout the liver rapidly disappear, even from viable, uninjured hepatocytes — an effect that can be blocked by the administration of antibodies to TNF-α and IFN-γ.34 Such noncytocidal antiviral effects may be important for viral clearance in natural infection. In fact, cytokine release triggered by unrelated hepatic infections in HBV-transgenic mice can have the same effect.36 This phenomenon may explain the suppression and occasional clearance of chronic HBV infection in patients with superimposed acute hepatitis caused by unrelated viruses.

Natural History

Primary HBV infection in susceptible (nonimmune) hosts can be either symptomatic or asymptomatic. The latter is more common than the former, especially in young children. Most primary infections in adults, whether symptomatic or not, are self-limited, with clearance of virus from blood and liver and the development of lasting immunity to reinfection.37,38 However, some primary infections in healthy adults (generally less than 5 percent) do not resolve but develop into persistent infections. In such cases, viral replication continues in the liver and there is continual viremia, although the titers of virus in the liver and blood are variable. Persistent HBV infection may be symptomatic or asymptomatic. People with subclinical persistent infection, normal serum aminotransferase levels, and normal or nearly normal findings on liver biopsy are termed asymptomatic chronic HBV carriers; those with abnormal liver function and histologic features are classified as having chronic hepatitis B. Cirrhosis, a condition in which regenerative nodules and fibrosis coexist with severe liver injury, develops in about 20 percent of people with chronic hepatitis B. The resulting hepatic insufficiency and portal hypertension make this process one of the most feared consequences of chronic HBV infection.

Primary Infection

In primary infection, HBsAg becomes detectable in the blood after an incubation period of 4 to 10 weeks, followed shortly by antibodies against the HBV core antigen (anti-HBc antibodies), which early in infection are mainly of the IgM isotype.38 Viremia is well established by the time HBsAg is detected, and titers of virus in acute infection are very high — frequently 10⁹ to 10¹⁰ virions per milliliter.39 Circulating HBeAg becomes detectable in most cases, and studies of chimpanzees and other animals with primary hepadnaviral infection show that 75 to 100 percent of hepatocytes are infected when this antigen is evident.40 Thus, it is not surprising that epidemiologic studies consistently show high rates of both vertical and horizontal transmissibility during acute HBV infection.41

When liver injury does occur in primary infection, alanine aminotransferase levels do not increase until after viral infection is well established, reflecting the time required to generate the T-cell–mediated immune response that triggers liver injury. Once this response is under way, titers of virus in blood and liver begin to drop. The fact that infection can be cleared from virtually all hepatocytes without massive hepatic destruction (in most cases) is a testament to the extraordinary power of the noncytolytic clearance mechanisms described above. With clearance of the infection, the viral antigens HBsAg and HBeAg disappear from the circulation, and free anti-HBs antibodies become detectable.

Surprisingly, in self-limited infection, as defined by the disappearance of the viral antigens and the appearance of anti-HBs antibodies, low levels of HBV DNA in the blood may persist for many years, if not for life.42 It is not known whether this DNA contains the entire HBV genome, or even whether it is contained in virions. However, inoculation of serum from three subjects with persistent HBV DNA into chimpanzees has not led to documented infectivity.42

Persistent Infection

In persistent HBV infection, the early events unfold as in self-limited infection, but HBsAg remains in the blood and virus production continues, often for life. However, levels of viremia in chronic infection are generally substantially lower than during primary infection, although they can vary considerably from person to person. High titers of HBV in the blood are often indicated by the continued presence of HBeAg. Typically, there are 10⁷ to 10⁹ virions per milliliter in the blood43 in such cases, which are highly infectious. But most people with persistent infection, especially those with anti-HBe antibodies, have somewhat lower levels of viremia.

One feature of chronic HBV infection that is not widely appreciated is its dynamic natural history. Even though, in most cases, HBsAg remains detectable for life, titers of viral DNA tend to decline over time. With the passage of time, there is also a tendency for HBeAg to disappear from the blood, along with seroconversion to positivity for anti-HBe antibodies — a progression that occurs at a rate of 5 to 10 percent per year in persistently infected people.39 Often, the disappearance of HBeAg is preceded or accompanied by a transient rise in alanine aminotransferase levels, known as a flare, which suggests that the process reflects immune-mediated destruction of infected hepatocytes. Reductions in the level of viremia as great as five orders of magnitude may accompany seroconversion to anti-HBe antibodies.44 Thus, the natural history of HBV persistence suggests that there is an ongoing immune attack on infected cells in the liver — an attack that is usually inadequate to eradicate infection altogether, but that does reduce the number of infected cells and thereby lowers the circulating viral load. Figure 4Figure 4Patterns of Serologic and Molecular Markers in HBV Infection. shows typical patterns of serologic and molecular markers in both acute self-limited and chronic HBV infection.

The widely held view that circulating viral DNA disappears when anti-HBe antibodies appear is incorrect; this idea reflects the fact that, for many years, HBV DNA was measured by relatively insensitive hybridization methods with a detection limit of 10⁵ to 10⁶ virions per milliliter. Thanks to the advent of the polymerase-chain-reaction (PCR) method, we now know that at least 70 to 85 percent of people with anti-HBe antibodies have detectable viral DNA in the circulation, typically in the range of 10³ to 10⁵ molecules per milliliter, and sometimes higher.44 Although these levels of HBV DNA are relatively low, they are hardly negligible. (For reference, they are similar to levels of human immunodeficiency virus [HIV] and HCV DNA in many patients with symptomatic acquired immunodeficiency syndrome or hepatitis C.) Given the short half-life of HBV virions (approximately one day),39 such levels can be sustained only by ongoing viral replication; therefore, the claim that HBV enters a so-called nonreplicative phase later in its course is not correct. For this reason, anyone who has a positive test for HBsAg should be presumed to have some level of ongoing viremia. For example, when a decision must be made about immunoprophylaxis after a needle stick involving blood from an HBsAg-positive patient, prophylaxis should be offered irrespective of that patient's HBeAg status.

HBeAg-negative carriers are a heterogeneous group. Most such carriers have low levels of viral DNA, relatively normal levels of alanine aminotransferase, and a good prognosis.30 However, particularly in southern Europe and in Asia, at least 15 to 20 percent of such carriers have elevated levels of alanine aminotransferase and viral DNA in the blood.45 The virus in many such carriers harbors mutations in the preC region that prevent the production of HBeAg.46 It has been suggested that persistently abnormal levels of alanine aminotransferase and elevated levels of viral DNA may denote a subgroup of HBeAg-negative carriers who should receive active antiviral therapy.47

Hepatocellular Carcinoma

Another feature of the natural history of HBV infection is its link to primary hepatocellular carcinoma. Chronically infected subjects have a risk of hepatocellular carcinoma that is 100 times as high as that for noncarriers48; within the HBsAg-positive group, HBeAg-positive carriers have the highest risk of hepatocellular carcinoma, but even carriers with anti-HBe antibodies have a substantial risk of cancer.49 (Although the role of HBV in provoking hepatocellular carcinoma is undisputed, its cellular and molecular mechanisms remain incompletely understood.50-54) Given these facts, twice-a-year screening of chronically infected patients with measurements of serum alpha fetoprotein or hepatic ultrasonography, or both, is warranted.47 However, there is debate as to when such screening should begin. Furthermore, screening is imperfect — alpha fetoprotein screening, for example, has an excellent negative predictive value, but its positive predictive value ranges from 9 to 30 percent.47

Implications for Therapy

The goals of therapy in patients with HBV infection are a reduction in the level of viremia and amelioration of hepatic dysfunction. Most clinical studies have focused on chronically infected patients with elevated aminotransferase levels and circulating HBeAg, in whom viral loads can be readily measured even with first-generation DNA tests. There are clear indications for therapy in HBeAg-positive patients. They have an increased risk of early progression to chronic active hepatitis and cirrhosis,55 and they have a risk of hepatocellular carcinoma that is substantially higher than that for other carriers.49 By contrast, asymptomatic HBeAg-negative chronic carriers with viral loads below 10⁵ genomes per milliliter and normal alanine aminotransferase values tend to have a relatively stable course, with low rates of clinical or pathological progression.30 At present, therapy is usually not offered to such persons. As noted above, some HBeAg-negative patients have liver dysfunction and substantial viremia (>10⁵ molecules per milliliter). Discussions of the treatment of such patients are rare in the published literature, but results of a recent trial suggest that many of these patients would also benefit from effective antiviral therapy.56 A recent clinical practice guideline47 includes this group in its discussion of treatment; clearly, future clinical investigations should focus more attention on this group.

The usual markers of successful therapy are the loss of HBeAg, seroconversion to anti-HBe antibodies, and reduction of the circulating viral load. These are useful indicators, since patients with stable seroconversion to anti-HBe–positive status typically have improved histologic findings in the liver, and this improvement tends to be maintained over the long term.57 True cure of infection (loss of HBsAg and complete disappearance of viremia, as measured by stringent PCR assays) is achieved only infrequently (in 1 to 5 percent of patients) with current regimens, although the increasing numbers of active antiviral drugs might lead to an upward revision of this figure in the future. In the case of patients with HBeAg-negative chronic hepatitis, there is no information about which markers best measure the response to therapy. Quantitation of viremia by PCR assays would seem a logical starting place, but there have been no systematic studies to guide the clinical interpretation of results.

Interferon

For many years, administration of interferon alfa (5 million to 10 million units subcutaneously three times per week, for at least three months) was the mainstay of therapy. About 30 percent of patients who tolerated this regimen had a successful response, defined as a loss of HBeAg, the development of anti-HBe antibodies, and a decline in serum alanine aminotransferase levels.58 With HBe seroconversion and normalization of alanine aminotransferase levels, improvement is usually sustained well after therapy has been discontinued.58 Interferon alfa treatment of chronic HBV infections in patients with cirrhosis has even been reported to reduce the risk of hepatocellular carcinoma.59

However, the side effects of therapy with interferon alfa (fever, myalgias, thrombocytopenia, and depression) make it a difficult treatment for many patients. Moreover, in many patients a flare of liver injury occurs during administration of interferon alfa, often just before or during clearance of HBeAg. This phenomenon may reflect the immunomodulatory activity of interferon alfa, which, in addition to impairing HBV replication, can also cause up-regulation of MHC class I antigens on hepatocytes and thereby augment the recognition of infected cells by cytotoxic T lymphocytes. Although sometimes disquieting to patients and physicians alike, these flares are intrinsic to the therapy and, as markers of enhanced antiviral immune responsiveness, often presage a successful outcome. However, treatment with interferon alfa is generally contraindicated in very advanced liver disease, since in such cases the flares may precipitate overt liver failure. Moreover, patients with advanced cirrhosis and splenomegaly usually have base-line leukopenia and thrombocytopenia, which can be exacerbated by the drug.

Antiviral Drugs

Lamivudine

In the past decade, therapy for HBV has been revolutionized by the advent of drugs that directly block replication of the HBV genome. All these drugs (to date) are nucleoside or nucleotide analogues that selectively target the viral reverse transcriptase. The first successful drug, lamivudine, emerged from screening for inhibitors of the HIV reverse transcriptase and was introduced into clinical practice for the management of HIV infection. Carriers of HIV who are also infected with HBV had substantial declines in HBV viremia when treated with lamivudine,60 and such declines were also observed in patients with chronic hepatitis B who did not have HIV infection.61 In general, treatment with lamivudine results in a reduction of 3 to 4 log in circulating levels of HBV DNA in the first three months of therapy; this decline is associated with more rapid loss of HBeAg, seroconversion to anti-HBe–positive status, and improvement in serum aminotransferase levels. The drug is usually well tolerated, a factor that has led to the rapid displacement of interferon alfa from the roster of first-line therapies for HBV. Lamivudine is not immunomodulatory and can be used in patients with decompensated cirrhosis.62 Even polyarteritis nodosa associated with HBV has been shown to respond dramatically to treatment with lamivudine plus plasma exchange.63

Although lamivudine is not an immunomodulator, there is strong evidence that successful treatment with lamivudine relies to some extent on an adequate host immune response. This evidence emerged from a retrospective examination of subgroups of patients with optimal responses to therapy, which revealed a strong correlation between HBeAg clearance and elevated pretreatment values for alanine aminotransferase.64 HBeAg seroconversion occurred in 65 percent of cases in which pretreatment values for alanine aminotransferase were more than five times the upper limit of the normal range, as compared with only 26 percent in patients with elevations in alanine aminotransferase values that were two to five times the upper limit of the normal range. Only 5 percent of patients with pretreatment alanine aminotransferase values that were less than twice the upper limit of the normal range had clearance of HBeAg — a rate similar to that for the spontaneous loss of this marker. This finding suggests that by reducing the viral load, lamivudine allows the immune and inflammatory responses to deal more effectively with the remaining infected hepatocytes in the host.

The principal limitation of lamivudine monotherapy is the development of drug resistance, which is mediated largely by point mutations at the YMDD motif at the catalytic center of the viral reverse transcriptase. The resulting mutants are slightly less fit than wild-type HBV in the absence of the drug, but they are strongly selected for in its presence.65 Viral resistance emerges much more slowly in HBV infection than in HIV infection, for complex reasons beyond the scope of this review. By the end of one year of therapy, 15 to 20 percent of patients have resistant variants in the circulation; the figure rises to 40 percent by two years, and to 67 percent by the fourth year.66

The clinical significance of the development of resistance is still being debated. Clearly, in many patients, resistance presages a return of higher-level viremia, and in some of these patients further liver injury develops. However, although the level of viremia rises, in many patients it may still remain below pretreatment levels — perhaps as a result of the reduced fitness of the variants. In addition, some patients continue to undergo conversion from HBeAg-positive status to HBeAg-negative status, even after the appearance of lamivudine-resistant mutants in the circulation; by the end of four years of therapy, 40 to 50 percent of patients treated with lamivudine have undergone such conversion. Therefore, some experts favor the continuation of lamivudine therapy in patients with resistant variants but no evidence of overt clinical failure, especially since transient exacerbations of liver injury develop in some patients when antiviral therapy is withdrawn.67 (Such postwithdrawal flares are not limited to lamivudine but have also been observed with other anti-HBV regimens.56,68) Now that newer anti-HBV drugs are available, additional options exist for patients with resistant strains of HBV.

Other Nucleotide Analogues

Recently, the Food and Drug Administration (FDA) approved a second antiviral drug, adefovir, to treat HBV infection. Adefovir, a nucleotide (adenosine monophosphate) analogue, is a prodrug that undergoes two intracellular phosphorylations to yield the active drug, an inhibitor of the viral polymerase. Initially developed as an inhibitor of HIV reverse transcriptase, it proved nephrotoxic in the doses that were required for effective inhibition of HIV replication. However, in lower doses (10 mg per day) it has shown little nephrotoxicity and retains good efficacy against HBV in HBeAg-positive patients, with a reduction of 3 to 4 log in viremia; the frequency of HBeAg seroconversion is enhanced, and there is histologic improvement in the liver.68 Similar efficacy was documented in HBeAg-negative patients with abnormal liver function and elevated levels of viral DNA.56 Moreover, the drug effectively inhibits the replication of lamivudine-resistant HBV mutants, both in vitro and in vivo.69,70 Clear evidence of the emergence of adefovir-resistant HBV mutants has not been found in the clinical trials performed to date,56,68,71 although this issue remains open now that large numbers of patients will be using the drug.

Tenofovir, another adenine nucleotide analogue that was approved by the FDA for the treatment of HIV, also has activity against the HBV polymerase. In recent trials in HIV carriers who were positive for HBeAg, treatment with standard doses of tenofovir led to a reduction of 4 log in circulating HBV DNA levels, even in patients who had evidence of lamivudine-resistant virus.72,73 However, the FDA has not yet approved tenofovir for use in patients with HBV infection.

Several investigational drugs are now in advanced stages of clinical trials. Entecavir is a guanosine analogue that, unlike the drugs discussed above, is highly selective for the HBV polymerase and has no activity against HIV. It is extremely potent on a molar basis, and doses as low as 0.1 mg per day can cause reductions of 4 log in levels of HBV DNA; a dose of 0.5 mg per day caused a reduction of nearly 5 log in 24 weeks of monotherapy.74 The drug is also active against lamivudine-resistant HBV. L-deoxythymidine is a thymidine analogue that also selectively inhibits the HBV polymerase and is advancing through clinical trials; it, too, appears to be active against lamivudine-resistant virus.75 Two other nucleoside analogues (emtricitabine and clevudine) have also shown promise in vitro and in vivo, although neither is reliably active against all lamivudine-resistant variants.76

Thus, the past few years have witnessed the development of a plethora of new drugs for the treatment of HBV infection. It seems likely that combination therapy will become the wave of the future in HBV therapy, but many questions remain to be resolved by clinical investigation. Is combination therapy truly superior to monotherapy, clinically as well as virologically? If, as most expect, it proves to be superior, which combination of drugs should be used for initial treatment? Will there be an evolution of cross-resistance among drugs that are effective against lamivudine-resistant viruses? What should be the duration of therapy? (One recent practice guideline recommends stopping antiviral therapy at one year in HBeAg-positive patients who have seroconversion to anti-HBe antibodies but continuing therapy in those who do not have seroconversion in the first year or in whom breakthrough viremia develops.47) More speculatively, could more potent combination therapy reduce HBV levels to a point where the remaining virus could be cleared by the host's own immune system, either spontaneously or after therapeutic vaccination with HBV antigens?

Liver Transplantation

Liver transplantation for HBV disease is attended by recurrent viral infection in more than 80 percent of patients if no interventions are undertaken to prevent reinfection.77 Recurrent HBV infection in the context of the level of immunosuppression needed to prevent graft rejection is typically associated with high viral loads and a poor outcome, especially for patients with chronic HBeAg-positive hepatitis. Hepatitis B immune globulin, administered over long periods, cuts the reinfection rate in half and extends the two-year survival rate from 50 percent to approximately 80 percent.77,78 Use of lamivudine after transplantation has resulted in similar improvement,79 but without question, the best results have been obtained with post-transplantation prophylaxis consisting of both hepatitis B immune globulin and lamivudine. This regimen reduces the rate of reinfection to about 10 percent and has boosted the five-year rate of HBV-free survival to approximately 80 percent.80 However, many problems remain. Hepatitis B immune globulin is very expensive and contributes substantially to the cost of transplantation. It seems likely that, in the near future, a more limited course of prophylaxis with hepatitis B immune globulin (6 to 12 months), in concert with long-term drug therapy, perhaps with more than one agent, will become popular. Whether the use of hepatitis B immune globulin can be avoided altogether by the use of multidrug regimens will require careful study.

Source Information

From the Departments of Microbiology and Immunology and Medicine and the Howard Hughes Medical Institute, University of California, San Francisco (D.G.); and the Laboratory of Virology, Lindsley F. Kimball Research Institute, New York Blood Center, and the Department of Pathology, New York University School of Medicine — both in New York (A.M.P.).

Address reprint requests to Dr. Prince at the Laboratory of Virology, Lindsley F. Kimball Research Institute, New York Blood Center, 310 E. 67th St., New York, NY 10021, or at aprince@nybloodcenter.org.

References

References

1. 1

   Krugman S, Giles JP, Hammond J. Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200:365-373
   CrossRef | Web of Science | Medline

2. 2

   Prince AM, Fuji H, Gershon RK. Immunohistochemical studies on the etiology of anicteric hepatitis in Korea. Am J Hyg 1964;79:365-381
   Web of Science | Medline

3. 3

   Chung WK, Moon SK, Gerson RK, Prince AM, Popper H. Anicteric hepatitis in Korea. II. Serial histologic studies. Arch Intern Med 1964;113:535-542
   Web of Science | Medline

4. 4

   Prince AM, Gershon RK. The etiology of chronic active hepatitis in Korea. Yale J Biol Med 1979;52:159-167
   Web of Science | Medline

5. 5

   Blumberg BS, Alter HJ, Visnich S. A “new“ antigen in leukemia sera. JAMA 1965;191:541-546
   Web of Science | Medline

6. 6

   Prince AM. Relation of Australia and SH antigens. Lancet 1968;2:462-463
   CrossRef | Web of Science | Medline

7. 7

   Prince AM. An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A 1968;60:814-821
   CrossRef | Web of Science | Medline

8. 8

   Prince AM, Hargrove RL, Szmuness W, Cherubin CE, Fontana VJ, Jeffries GH. Immunologic distinction between infectious and serum hepatitis. N Engl J Med 1970;282:987-991
   Full Text | Web of Science | Medline

9. 9

   Krugman S, Giles JP. Viral hepatitis: new light on an old disease. JAMA 1970;212:1019-1029
   CrossRef | Web of Science | Medline

10. 10

    Marion PL. Use of animal models to study hepatitis B viruses. Prog Med Virol 1988;35:43-75
    Medline

11. 11

    Korba BE, Gowans EJ, Wells FV, Tennant BC, Clarke R, Gerin JL. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology 1988;165:172-181
    CrossRef | Web of Science | Medline

12. 12

    Halpern MS, England JM, Deery DT, Petcu DJ, Mason WS, Molnar-Kimber KL. Viral nucleic acid synthesis and antigen accumulation in pancreas and kidney of Peking ducks infected with duck hepatitis B virus. Proc Natl Acad Sci U S A 1983;80:4865-4869
    CrossRef | Web of Science | Medline

13. 13

    Barker LF, Maynard JE, Purcell RH, et al. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis 1975;132:451-458
    CrossRef | Web of Science | Medline

14. 14

    Dane DS, Cameron CH, Briggs M. Virus-like particles in the serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-698
    CrossRef | Web of Science | Medline

15. 15

    Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 1991;168:61-83
    Web of Science | Medline

16. 16

    Robinson WS, Lutwick LI. The virus of hepatitis, type B. N Engl J Med 1976;295:1168-1175
    Full Text | Web of Science | Medline

17. 17

    Summers J, O'Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci U S A 1975;72:4597-4601
    CrossRef | Web of Science | Medline

18. 18

    Kao J-H. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650
    CrossRef | Web of Science | Medline

19. 19

    Ganem D, Schneider RJ. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology, 4th ed. Vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2001:2923-69.
    

20. 20

    Klingmuller U, Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol 1993;67:7414-7422
    Web of Science | Medline

21. 21

    Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 1991;88:1059-1063
    CrossRef | Web of Science | Medline

22. 22

    Takahashi K, Machida A, Funatsu G, et al. Immunochemical structure of hepatitis B e antigen in the serum. J Immunol 1983;130:2903-2907
    Web of Science | Medline

23. 23

    Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990;64:1298-1303
    Web of Science | Medline

24. 24

    Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994;68:2026-2030
    Web of Science | Medline

25. 25

    Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415
    CrossRef | Web of Science | Medline

26. 26

    Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-460
    CrossRef | Web of Science | Medline

27. 27

    Will H, Reiser W, Weimer T, et al. Replication strategy of human hepatitis B virus. J Virol 1987;61:904-911
    Web of Science | Medline

28. 28

    Pollack JR, Ganem D. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J Virol 1994;68:5579-5587
    Web of Science | Medline

29. 29

    Wang GH, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 1993;67:6507-6512
    Web of Science | Medline

30. 30

    de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-194
    Web of Science | Medline

31. 31

    Stevens CE, Beasley RP, Tsui J, Lee W-C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-774
    Full Text | Web of Science | Medline

32. 32

    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
    CrossRef | Web of Science | Medline

33. 33

    Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:149-173
    Web of Science | Medline

34. 34

    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36
    CrossRef | Web of Science | Medline

35. 35

    Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002;16:583-594
    CrossRef | Web of Science | Medline

36. 36

    Cavanaugh VJ, Guidotti LG, Chisari FV. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 1998;72:2630-2637
    Web of Science | Medline

37. 37

    Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-1344
    CrossRef | Web of Science | Medline

38. 38

    Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu Rev Med 1981;32:1-11
    CrossRef | Web of Science | Medline

39. 39

    Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes Infect 2002;4:829-835
    CrossRef | Web of Science | Medline

40. 40

    Kajino K, Jilbert AR, Saputelli J, Aldrich CE, Cullen J, Mason WS. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol 1994;68:5792-5803
    Web of Science | Medline

41. 41

    Koff RS, Slavin MM, Connelly JD, Rosen DR. Contagiousness of acute hepatitis B: secondary attack rates in household contacts. Gastroenterology 1977;72:297-300
    Web of Science | Medline

42. 42

    Prince AM, Lee D-H, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001;41:329-332
    CrossRef | Web of Science | Medline

43. 43

    Weinberger KM, Wiedenmann E, Bohm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods 2000;85:75-82
    CrossRef | Web of Science | Medline

44. 44

    Tedder RS, Ijaz S, Gilbert N, et al. Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. J Med Virol 2002;68:505-512
    CrossRef | Web of Science | Medline

45. 45

    Sung J, Chan HL-Y, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002;9:229-234
    CrossRef | Web of Science | Medline

46. 46

    Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991;88:4186-4190
    CrossRef | Web of Science | Medline

47. 47

    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241
    CrossRef | Web of Science | Medline

48. 48

    Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956
    CrossRef | Web of Science | Medline

49. 49

    Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174
    Free Full Text | Web of Science | Medline

50. 50

    Fourel G, Trepo C, Bougueleret L, et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990;347:294-298
    CrossRef | Web of Science | Medline

51. 51

    Matsubara K, Tokino F. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990;7:243-260
    Medline

52. 52

    Popper H, Roth L, Purcell RH, Tennant BC, Gerin JL. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A 1987;84:866-870
    CrossRef | Web of Science | Medline

53. 53

    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320
    CrossRef | Web of Science | Medline

54. 54

    Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene. J Virol 1992;66:5284-5289
    Web of Science | Medline

55. 55

    Liaw YF, Tai DI, Chu CM, Chen TJ. Development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-496
    CrossRef | Web of Science | Medline

56. 56

    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807[Erratum, N Engl J Med 2003;348:1192.]
    Free Full Text | Web of Science | Medline

57. 57

    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427
    Free Full Text | Web of Science | Medline

58. 58

    Wong DK, Cheung A, O'Rourke K, et al. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-323
    Web of Science | Medline

59. 59

    Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827-835
    CrossRef | Web of Science | Medline

60. 60

    Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002;4:27-35
    Medline

61. 61

    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
    Free Full Text | Web of Science | Medline

62. 62

    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210
    CrossRef | Web of Science | Medline

63. 63

    Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001;16:269-274
    CrossRef | Web of Science | Medline

64. 64

    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-774
    CrossRef | Web of Science | Medline

65. 65

    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633
    CrossRef | Web of Science | Medline

66. 66

    Liaw YF, Cheung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180
    CrossRef | Web of Science | Medline

67. 67

    Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639
    CrossRef | Web of Science | Medline

68. 68

    Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
    Free Full Text | Web of Science | Medline

69. 69

    Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000;7:161-165
    CrossRef | Web of Science | Medline

70. 70

    Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
    CrossRef | Web of Science | Medline

71. 71

    Yang H, Westland CE, Delaney WE IV, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473
    CrossRef | Web of Science | Medline

72. 72

    Nelson M, Portsmouth J, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10
    CrossRef | Web of Science | Medline

73. 73

    Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847
    CrossRef | Web of Science | Medline

74. 74

    Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838
    CrossRef | Web of Science | Medline

75. 75

    Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12:Suppl 1:119-129
    Medline

76. 76

    Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001;45:2495-2501
    CrossRef | Web of Science | Medline

77. 77

    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847
    Free Full Text | Web of Science | Medline

78. 78

    Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333
    CrossRef | Web of Science | Medline

79. 79

    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-1586
    CrossRef | Web of Science | Medline

80. 80

    Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: 17-year single-center experience. Ann Surg 2002;235:611-620
    CrossRef | Web of Science | Medline

Citing Articles (548)

Citing Articles

1. 1

   Wei Cui, Cui-Ming Sun, Bao-Cheng Deng, Pei Liu. (2013) Association of polymorphisms in the interleukin-4 gene with response to hepatitis B vaccine and susceptibility to hepatitis B virus infection: A meta-analysis. Gene 525:1, 35-40
   

2. 2

   Xiaoxiao Gai, Peiqing Zhao, Yingfang Pan, Haixia Shan, Xuetian Yue, Juan Du, Zhenyu Zhang, Peng Liu, Hongxin Ma, Min Guo, Xiaoyun Yang, Wensheng Sun, Lifen Gao, Chunhong Ma, Xiaohong Liang. (2013) Hepatitis B virus core protein enhances human telomerase reverse transcriptase expression and hepatocellular carcinoma cell proliferation in a c-Ets2-dependent manner. The International Journal of Biochemistry & Cell Biology 45:7, 1174-1185
   

3. 3

   Matthew D Sadler, Carla S Coffin, Samuel S Lee. (2013) Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opinion on Pharmacotherapy 14:10, 1363-1369
   

4. 4

   Dan Wu, Honglei Jiang, Qiuhong Gu, Dan Zhang, Zhiwei Li. (2013) Association between XRCC1 Arg399Gln polymorphism and hepatitis virus-related hepatocellular carcinoma risk in Asian population. Tumor Biology
   

5. 5

   Zhen Zheng, Xu Li, Zhiliang Li, Xiao-Chun Ma. (2013) IL-4 −590C/T Polymorphism and Susceptibility to Liver Disease: A Meta-Analysis and Meta-Regression. DNA and Cell Biology130615073357006
   

6. 6

   Tzu-Wei Wu, Chen-Chung Chu, Tzu-Ying Ho, Huei-Wen Chang Liao, Sheng-Kai Lin, Marie Lin, Hans Hsienhong Lin, Li-Yu Wang. (2013) Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Human Genetics
   

7. 7

   Scully , Eileen P. , Klompas , Michael , Morgan , Elizabeth A. , Miller , Amy Leigh , Loscalzo , Joseph , . (2013) Waiting for the Other Foot to Drop. New England Journal of Medicine 368:23, 2220-2225
   Full Text

8. 8

   Samuel Martín-Vílchez, Ricardo Moreno-Otero, Paloma Sanz-Cameno. (2013) Mecanismos de acción y efectos de la proteína X (HBx) en la patogenia de la hepatitis crónica B. Medicina Clínica 140:11, 508-513
   

9. 9

   Pingnan Sun, Junhong Zheng, Guizhou She, Xiujing Wei, Xiaoyu Zhang, Haijun Shi, Xiaoling Zhou. (2013) Expression pattern of asialoglycoprotein receptor in human testis. Cell and Tissue Research 352:3, 761-768
   

10. 10

    Pin-Nan Cheng, Hung-Wen Tsai, Yen-Cheng Chiu, Cheng-Hsun Ho, I-Chin Wu, Ting-Tsung Chang. (2013) Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. Journal of Clinical Virology
    

11. 11

    Marketa Vaculovicova, Kristyna Smerkova, Jiri Sedlacek, Jiri Vyslouzil, Jaromir Hubalek, Rene Kizek, Vojtech Adam. (2013) Integrated chip electrophoresis and magnetic particle isolation used for detection of hepatitis B virus oligonucleotides. ELECTROPHORESIS 34:11, 1548-1554
    

12. 12

    Fan-wei Liu, Dong-bo Wu, En-qiang Chen, Cong Liu, Li Liu, Shou-chun Chen, Dao-yin Gong, Lian-san Zhao, Hong Tang, Tao-you Zhou. (2013) Expression of TRAIL in liver tissue from patients with different outcomes of HBV infection. Clinics and Research in Hepatology and Gastroenterology 37:3, 269-274
    

13. 13

    T. Requena, M. T. Martin, T. Desongles, I. Castillo, L. Lorente, M. Yebenes, , E. Abad, J. Alfaro, M. A. Calleja, M. Fernandez, C. Garcia, R. Garriga, E. Gutierrez, P. Iglesias, A. Illaro, I. Jimenez, A. Lopez, L. Margusino, S. Martin, J. M. Martinez, E. Monte, A. Morell, M. C. Moriel, I. Moya, H. Navarro, N. Pola, M. J. Polache, J. M. Prada, M. A. Rodriguez, J. S. Roldan, C. Rosado, N. Rudi, M. J. Sanchez, E. Sanchez, B. Tortajada, O. Urbina, P. Ventayol, A. Ais, A. Arrondo, M. Casas, S. De Andres, A. De Frutos, E. Del Cacho, V. Faus, J. M. Fernandez, O. Ferrandez, M. Ferrit, B. Fuentes, C. Gil, V. Gonzalez, L. Gonzalez, T. Gramage, S. Grutzmancher, M. O. Ibarra, E. Ibarra, M. J. Izquierdo, C. Lamela, B. Larrayoz, J. Llorente, S. Lopez, A. M. Lopez, A. Martinez, C. Martinez, M. Massanes, L. Menendez, P. Miranda, M. Saez, L. Ordonez, J. J. Ortiz, M. T. Paredes, R. Pellicer, G. Pineiro, M. Pio, S. Plata, J. L. Poveda, J. F. Rangel, A. Raso, D. Rincon, S. Rivero, B. Rodriguez Vargas, B. Rubio Cebrian, E. Salas Sanchez, M. T. Sanchez, E. Sanchez, J. Selva, J. Serna, M. Sevilla, G. Silva, F. Suarez, N. Trovato, A. Urrutia, P. Vazquez, N. Vilardell, N. Villen. (2013) Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study. European Journal of Hospital Pharmacy: Science and Practice 20:3, 174-179
    

14. 14

    Yaping Han, Jun Li, Longfeng Jiang, Qingqing Xu, Bo Liu, Ke Jin, Yuan Liu, Zuhu Huang. (2013) Regulation of B7-H1 expression on peripheral monocytes and IFN-γ secretion in T lymphocytes by HBeAg. Cellular Immunology
    

15. 15

    Chan-Juan Zou, Lang-Jing Zhu, Yan-Hua Li, Ying-Qian Mo, Dong-Hui Zheng, Jian-Da Ma, Xia Ou-Yang, Frank Pessler, Lie Dai. (2013) The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clinical Rheumatology 32:6, 787-795
    

16. 16

    W H Y Ling, P P Soe, A S L Pang, S-C Lee. (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. British Journal of Cancer 108:10, 1931-1935
    

17. 17

    Turyadi, Meta Dewi Thedja, Susan Irawati Ie, Alida Roswita Harahap, Korri Elvanita El-Khobar, Martono Roni, David Handojo Muljono. (2013) HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients. Hepatology International
    

18. 18

    Yan Wang, Ming-Yi Xu, Rui-Dan Zheng, Jian-Chun Xian, Hong-Tao Xu, Jun-Ping Shi, Shi-Bo Li, Ying Qu, Yu-Wei Dong, Lun-Gen Lu. (2013) Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatology Research 43:5, 441-451
    

19. 19

    Chih-Lin Lin, Jia-Horng Kao. (2013) Hepatitis B Virus Genotypes: Clinical Relevance and Therapeutic Implications. Current Hepatitis Reports
    

20. 20

    H. Wang, L. Xue, R. Yan, Y. Zhou, M. S. Wang, M. J. Cheng, H. J. Huang. (2013) Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. Journal of Viral Hepatitis 20:4, e3-e10
    

21. 21

    R. S. Tedder, A. J. Rodger, L. Fries, S. Ijaz, M. Thursz, W. Rosenberg, N. Naoumov, J. Banatvala, R. Williams, G. Dusheiko, S. Chokshi, T. Wong, G. Rosenberg, S. Moreea, M. Bassendine, M. Jacobs, P. R. Mills, D. Mutimer, S. D. Ryder, A. Bathgate, H. Hussaini, J. F. Dillon, M. Wright, G. Bird, J. Collier, M. Anderson, A. M. Johnson, . (2013) The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. Clinical Infectious Diseases 56:7, 951-960
    

22. 22

    Li-Shuai Qu, Jing Zhu, Hong Chen, Fei Jin, Run-Zhou Ni, Cui-Hua Lu. (2013) Effects of hepatitis B e-antigen on recurrence of hepatitis B-related hepatocellular carcinoma after curative resection: A meta-analysis. Hepatology Research 43:4, 347-354
    

23. 23

    Tsutomu Nishida, Naoki Hiramatsu, Masao Mizuki, Izumi Nagatomo, Hiroshi Kida, Keiko Tazumi, Shinichiro Shinzaki, Masanori Miyazaki, Takayuki Yakushijin, Tomohide Tatsumi, Hideki Iijima, Shinichi Kiso, Tatsuya Kanto, Masahiko Tsujii, Tetsuo Takehara. (2013) Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatology Research 43:4, 339-346
    

24. 24

    Timothy M. Block, Robert Gish, Haitao Guo, Anand Mehta, Andrea Cuconati, W. Thomas London, Ju-Tao Guo. (2013) Chronic hepatitis B: What should be the goal for new therapies?. Antiviral Research 98:1, 27-34
    

25. 25

    Qing Fang, You-hua Hao, Lei Li, Zhen-hua Zhang, Jun-zhong Wang, Ming-fa Chen, Jian Kang, Dong-liang Yang. (2013) Chronic HBV Carrier’s acceptance of regular surveilling program in China. Journal of Huazhong University of Science and Technology [Medical Sciences] 33:2, 288-292
    

26. 26

    Yan J. Pang, Xiao J. Tan, Dong M. Li, Zi H. Zheng, Rui X. Lei, Xiao M. Peng. (2013) Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus. Liver Internationaln/a-n/a
    

27. 27

    Ya-Ling Chiou, Chia-Ju Shih, Wang-Sheng Ko. (2013) The increased ratio of CD4+/CD8+ was positively correlated with inflammation in hepatitis C patients with metabolic syndrome. Clinical Biochemistry
    

28. 28

    Wenjuan Gao, Yuhan Sun, Shiwen Chen, Jingyao Zhang, Jingjing Kang, Yongqiang Wang, Hexiang Wang, Guoliang Xia, Qinghong Liu, Youmin Kang. (2013) Mushroom lectin enhanced immunogenicity of HBV DNA vaccine in C57BL/6 and HBsAg-transgenic mice. Vaccine 31:18, 2273-2280
    

29. 29

    Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap-Sun Yeung, Makonen Belema, Mark Krystal. Antiviral Drug Discovery. In: Drug Discovery. John Wiley & Sons, Inc., 2013:439-515.
    

30. 30

    T. Zhang, J. Cai, J. Chang, D. Yu, C. Wu, T. Yan, K. Zhai, X. Bi, H. Zhao, J. Xu, W. Tan, C. Qu, D. Lin. (2013) Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Human Molecular Genetics 22:6, 1262-1269
    

31. 31

    Gang Luo, Ning-Bo Hao, Chang-Jiang Hu, Xin Yong, Mu-Han Lü, Bo-Jun Cheng, Yao Zhang, Shi-Ming Yang. (2013) HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes & Control 24:3, 529-537
    

32. 32

    Zhen Wang, Xiao-Qiang Zhao. (2013) A Within-Host Virus Model with Periodic Multidrug Therapy. Bulletin of Mathematical Biology 75:3, 543-563
    

33. 33

    R. Navarro, E. Vilarrasa, P. Herranz, L. Puig, X. Bordas, J.M. Carrascosa, R. Taberner, M. Ferrán, M. García-Bustinduy, A. Romero-Maté, R. Pedragosa, A. García-Diez, E. Daudén. (2013) Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. British Journal of Dermatology 168:3, 609-616
    

34. 34

    Carlo Saitta, Cristina Musolino, Grazia Marabello, Daniela Martino, Maria Silvana Leonardi, Teresa Pollicino, Giuseppe Altavilla, Giovanni Raimondo. (2013) Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy. Digestive and Liver Disease
    

35. 35

    Shuping Tong, Jisu Li, Jack R Wands, Yu-mei Wen. (2013) Hepatitis B virus genetic variants: biological properties and clinical implications. Emerging Microbes & Infections 2:3, e10
    

36. 36

    FW Chen, L Coyle, BE Jones, V Pattullo. (2013) Entecavir versus lamivudine for hepatitis b prophylaxis in patients with haematological disease. Liver Internationaln/a-n/a
    

37. 37

    Camille Sureau, Jessica Salisse. (2013) A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus A-determinant. Hepatology 57:3, 985-994
    

38. 38

    Masataka Tsuge, Eisuke Murakami, Michio Imamura, Hiromi Abe, Daiki Miki, Nobuhiko Hiraga, Shoichi Takahashi, Hidenori Ochi, C. Nelson Hayes, Hiroyuki Ginba, Kazuhiro Matsuyama, Hiroiku Kawakami, Kazuaki Chayama. (2013) Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. Journal of Gastroenterology
    

39. 39

    Meirong Wang, Ning Qiu, Shichun Lu, Dianrong Xiu, Jianguo Yu, Xing tai Wang, Fengmin Lu, Tong Li, Xueen Liu, Hui Zhuang. (2013) Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. Journal of Medical Virology 85:2, 219-227
    

40. 40

    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin. (2013) The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver International 33, 125-132
    

41. 41

    Lucio Boglione, Antonio D’Avolio, Giuseppe Cariti, Giovanni Di Perri. (2013) Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. Journal of Clinical Virology 56:2, 167-169
    

42. 42

    Annabelle Servant-Delmas, Claude Chuteau, Caroline Lefort, Yves Piquet, Sylvie Chevaleyre, Véronique Betbeze, Martine Delhoume, Sébastien Hantz, Sophie Alain, Syria Laperche. (2013) Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing. Transfusion 53:2, 291-296
    

43. 43

    Mustafa Sunbul, Masaya Sugiyama, Fuat Kurbanov, Hakan Leblebicioglu, Anis Khan, Abeer Elkady, Yasuhito Tanaka, Masashi Mizokami. (2013) Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. Microbiology and Immunology 57:2, 122-129
    

44. 44

    S. Shrivastava, N. TrehanPati, S. Patra, S. Kottilil, C. Pande, S. S. Trivedi, S. K. Sarin. (2013) Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns. Journal of Viral Hepatitisn/a-n/a
    

45. 45

    Diego F. Calvisi, Roberto J. Groszmann, Yasuko Iwakiri, Tamar H. Taddei. (2013) Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: A revolution in hepatocellular carcinoma prevention?. Hepatology 57:2, 848-850
    

46. 46

    Arjan Boltjes, Marjoleine L. Op den Brouw, Paula J. Biesta, Rekha S. Binda, Renate G. van der Molen, Andre Boonstra, Harry L.A. Janssen, Andrea M. Woltman. (2013) Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients. Molecular Immunology 53:1-2, 72-78
    

47. 47

    Gillian K. Rosenberg, Sam Lattimore, Susan R. Brailsford, Patricia E. Hewitt, Kate I. Tettmar, Alan D. Kitchen, Samreen Ijaz, Richard S. Tedder. (2013) The diversity of chronic hepatitis B virus infections within blood donors in England and North Wales 2005 through 2010. Transfusionn/a-n/a
    

48. 48

    M. Mouler Rechtman, E. O. Burdelova, I. Bar-Yishay, M. Ben-Yehoyada, S. Fishman, Z. Halpern, A. Shlomai. (2013) The metabolic regulator PGC-1α links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus. Journal of Viral Hepatitis 20:1, 34-41
    

49. 49

    Winnie Yeo, Henry LY Chan. (2013) Hepatitis B virus reactivation associated with anti-neoplastic therapy. Journal of Gastroenterology and Hepatology 28:1, 31-37
    

50. 50

    María Buti, Itziar Oyagüez, Virginia Lozano, Miguel A. Casado. (2013) Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B. PharmacoEconomics 31:1, 63-75
    

51. 51

    Mario Mandalà, Stefano Fagiuoli, Daniela Francisci, Raffaele Bruno, Barbara Merelli, Luisa Pasulo, Carlo Tondini, Roberto Labianca, Fausto Roila. (2013) Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis. Critical Reviews in Oncology/Hematology
    

52. 52

    H. Jiang, J. Wang, W. Zhao. (2013) Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 32:1, 11-18
    

53. 53

    Paolo De Paoli, Antonino Carbone. (2013) Carcinogenic viruses and solid cancers without sufficient evidence of causal association. International Journal of Cancern/a-n/a
    

54. 54

    Eduardo Vázquez Martul. (2013) Orientación diagnóstica de las enfermedades renales glomerulares. Revista Española de Patología 46:1, 3-13
    

55. 55

    Frank A. Wollheim, Monika Ronneberger. Enteropathic Arthritis. In: Kelley's Textbook of Rheumatology. Elsevier, 2013:1251-1268.
    

56. 56

    Tao Chen, Lin Zhu, Yaoyong Zhou, Bin Pi, Xiaojuan Liu, Guohong Deng, Rong Zhang, Yuming Wang, Zeguang Wu, Meifang Han, Xiaoping Luo, Qin Ning. (2013) KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. Clinical Immunology
    

57. 57

    Anja Meier, Stefan Mehrle, Thomas S. Weiss, Walter Mier, Stephan Urban. (2013) Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatologyn/a-n/a
    

58. 58

    Jung-In Choi, Ji-Hun Lim, Joseph Jeong, Seon-Ho Lee, Jae-Sun Park, Neung Hwa Park, Jung Woo Shin, Yang Won Nah, Chang Woo Nam, Young Joo Cha, Sung-Ryul Kim. (2013) Performance Evaluation of Immunoassay Detection of HBsAg Mutants and Their Clinical Significance in the High Risk Groups. Laboratory Medicine Online 3:2, 88
    

59. 59

    Nghiem B. Ha, Nghi B. Ha, Huy N. Trinh, Huy A. Nguyen, Khanh K. Nguyen, Mindie H. Nguyen. (2013) Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily. Journal of Clinical Gastroenterology 47:5, 461-465
    

60. 60

    Yu Zhao, Xiao-jun Gou, Jian-ye Dai, Jing-hua Peng, Qin Feng, Shu-jun Sun, Hui-juan Cao, Ning-ning Zheng, Jun-wei Fang, Jian Jiang, Shi-bing Su, Ping Liu, Yi-yang Hu, Yong-yu Zhang. (2013) Differences in Metabolites of Different Tongue Coatings in Patients with Chronic Hepatitis B. Evidence-Based Complementary and Alternative Medicine 2013, 1-12
    

61. 61

    Sara I. Ruiz, Elizabeth E. Zumbrun, Aysegul Nalca. Animal Models of Human Viral Diseases. In: Animal Models for the Study of Human Disease. Elsevier, 2013:927-970.
    

62. 62

    Mark Danta, Arthur Y Kim. Hepatobiliary Diseases. In: Hunter's Tropical Medicine and Emerging Infectious Disease. Elsevier, 2013:28-34.
    

63. 63

    Kiyoshi Migita, Seigo Abiru, Masashi Ohtani, Yuka Jiuchi, Yumi Maeda, Sung Kwan Bae, Shigemune Bekki, Satoru Hashimoto, Kakharman Yesmembetov, Shinya Nagaoka, Minoru Nakamura, Atsumasa Komori, Tatsuki Ichikawa, Kazuhiko Nakao, Hiroshi Yatsuhashi, Hiromi Ishibashi, Michio Yasunami. (2012) HLA-DP gene polymorphisms and hepatitis B infection in the Japanese population. Translational Research 160:6, 443-444
    

64. 64

    Lucy Lim, Bang Manh Tran, Elizabeth Vincan, Stephen Locarnini, Nadia Warner. (2012) HBV-related hepatocellular carcinoma: the role of integration, viral proteins and miRNA. Future Virology 7:12, 1237-1249
    

65. 65

    Ryu Watanabe, Tomonori Ishii, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, Hiroshi Fujii, Hideo Harigae. (2012) Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy. Modern Rheumatology
    

66. 66

    Yan Zhong, Jing Wang, Yao Wang, Bin Wu. (2012) Preparation and evaluation of liposome-encapsulated codrug LMX. International Journal of Pharmaceutics 438:1-2, 240-248
    

67. 67

    Ya-Lin Chiou, Yi-Hui Chen, Tiffany Ke, Wang-Sheng Ko. (2012) The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients. Clinical Biochemistry 45:16-17, 1389-1393
    

68. 68

    Jing-jing Ren, Xue-wei Dai, Zheng-gang Jiang, Ling-zhi Shen, Yong-di Chen, Qian Li, Wen Ren, Ying Liu, Jun Yao, Lan-juan Li. (2012) Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults. Journal of Zhejiang University SCIENCE B 13:11, 948-954
    

69. 69

    Chun-Hui Yan, Cheng-Yu Zhao, Hai Ding, Ya-Qin Peng, Peng-Yuan Jin, Ling Yan, Hui Zhuang, Tong Li. (2012) Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Research 96:2, 108-114
    

70. 70

    Qingzhou Luo, Yandan Zhong, Yongfeng Yang, Qingfang Xiong, Zhiliang Hu, Weiming Lu, Ping Huang, Ning Zhang. (2012) Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains. Journal of Medical Virology 84:10, 1558-1561
    

71. 71

    Carol Strong, Sunmin Lee, Miho Tanaka, Hee-Soon Juon. (2012) Ethnic Differences in Prevalence and Barriers of HBV Screening and Vaccination Among Asian Americans. Journal of Community Health 37:5, 1071-1080
    

72. 72

    J. W. Shin, S. W. Jung, B. R. Park, C. J. Kim, J. B. Eum, B. G. Kim, I. D. Jeong, S.-J. Bang, S.-H. Lee, S. R. Kim, N. H. Park. (2012) Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. Journal of Viral Hepatitis 19:10, 724-731
    

73. 73

    Ke Ma, Wei Guo, Meifang Han, Guang Chen, Tao Chen, Zenguang Wu, Daofeng Yang, Jiaquan Huang, Yuancheng Huang, Xiping Zhao, Deying Tian, Jianxin Song, Junying Qi, Qin Ning. (2012) Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatology International 6:4, 735-743
    

74. 74

    Seung Ha Park. (2012) Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population. International Journal of Infectious Diseases 16:9, e669-e672
    

75. 75

    Patrick T.F. Kennedy, Elena Sandalova, Juandy Jo, Upkar Gill, Ines Ushiro–Lumb, Anthony T. Tan, Sandhia Naik, Graham R. Foster, Antonio Bertoletti. (2012) Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. Gastroenterology 143:3, 637-645
    

76. 76

    Mohamed M.S. Farag, Raindy Tedjokusumo, Christa Flechtenmacher, Theresa Asen, Wolfgang Stremmel, Martina Müller, Ulrike Protzer, Kilian Weigand. (2012) Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 30:42, 6034-6039
    

77. 77

    Andrew J. Prendergast, Paul Klenerman, Philip J. R. Goulder. (2012) The impact of differential antiviral immunity in children and adults. Nature Reviews Immunology 12:9, 636-648
    

78. 78

    Kangmei Chen, Hanyi Min, Xiaopan Wu, Xilin Zhu, Zhuo Li, Hui Li, Ying Liu. (2012) JAK1 Gene Polymorphisms Are Associated with the Outcomes of Hepatitis B Virus Infection, But Not with α Interferon Therapy Response in a Han Chinese Population. Genetic Testing and Molecular Biomarkers120817090358007
    

79. 79

    G. Sitia, R. Aiolfi, P. Di Lucia, M. Mainetti, A. Fiocchi, F. Mingozzi, A. Esposito, Z. M. Ruggeri, F. V. Chisari, M. Iannacone, L. G. Guidotti. (2012) From the Cover: PNAS Plus: Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences 109:32, E2165-E2172
    

80. 80

    Pattaratida Sa-nguanmoo, Pisit Tangkijvanich, Piyanit Tharmaphornpilas, Aim-orn Rasdjarmrearnsook, Saowanee Plianpanich, Nutchanart Thawornsuk, Apiradee Theamboonlers, Yong Poovorawan. (2012) Molecular analysis of hepatitis B virus associated with vaccine failure in infants and mothers: A case-control study in Thailand. Journal of Medical Virology 84:8, 1177-1185
    

81. 81

    Wei Tu, Min Luo, Zhijun Wang, Wei Yan, Yujia Xia, Huan Deng, Jiayi He, Ping Han, Dean Tian. (2012) Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver International 32:7, 1064-1078
    

82. 82

    M. M. YU, X. J GU, Y. XIA, G. J. WANG, N. Y. KAN, H. X. JIANG, K. H. WU, Y. JI, L. L. JU. (2012) Relationship between HBV cccDNA expression in the human ovary and vertical transmission of HBV. Epidemiology and Infection 140:08, 1454-1460
    

83. 83

    Warda Baha, My Mustapha Ennaji, Fatiha Lazar, Marouane Melloul, Elmostafa El Fahime, Abdelouahad El Malki, Abdelouaheb Bennani. (2012) HBV genotypes prevalence, precore and basal core mutants in Morocco. Infection, Genetics and Evolution 12:6, 1157-1162
    

84. 84

    T.A. Sallam, Y.A. Raja‘a, S. Bahaj, A.M. Al-Shami, M. Lu, M. Roggendorf, C.Y.W. Tong. (2012) Hepatitis B virus carrier rate, prevalence and susceptibility and impact of immunization program among households in the city of Taiz, Yemen. Vaccine 30:37, 5564-5568
    

85. 85

    Guillaume Fallot, Christine Neuveut, Marie-Annick Buendia. (2012) Diverse roles of hepatitis B virus in liver cancer. Current Opinion in Virology 2:4, 467-473
    

86. 86

    Giovanni Raimondo, Gaia Caccamo, Roberto Filomia, Teresa Pollicino. (2012) Occult HBV infection. Seminars in Immunopathology
    

87. 87

    Mansour Sheikhan, S. Amir Ghoreishi. (2012) Application of covariance matrix adaptation–evolution strategy to optimal control of hepatitis B infection. Neural Computing and Applications
    

88. 88

    F. ZOULIM, F. BAILLY, M. JOHNSON, C. KESSLER. (2012) Treatment of human immunodeficiency virus and hepatitis B virus infections. Haemophilia 18, 34-37
    

89. 89

    Mingjie Li, Mehmet A. Orgun, Jinghua Xiao, Weicai Zhong, Liyin Xue. (2012) The impact of human activity patterns on asymptomatic infectious processes in complex networks. Physica A: Statistical Mechanics and its Applications 391:14, 3718-3728
    

90. 90

    Yan Chen, Xia Xie, Lin Gu, Xiao-Hui Huang, Xiao-Mou Peng. (2012) Furin mRNA expression in peripheral blood correlates with chronic hepatitis B virus infection. Hepatology Researchno-no
    

91. 91

    Thulasamma Parusu, Venkateswarlu Ponneri. (2012) RP-HPLC method for simultaneous determination of atenolol and indapamide in pharmaceutical dosage forms, human blood and milk. European Journal of Chemistry 3:2, 138-142
    

92. 92

    Sebastian Zeissig, Kazumoto Murata, Lindsay Sweet, Jean Publicover, Zongyi Hu, Arthur Kaser, Esther Bosse, Jahangir Iqbal, M Mahmood Hussain, Katharina Balschun, Christoph Röcken, Alexander Arlt, Rainer Günther, Jochen Hampe, Stefan Schreiber, Jody L Baron, D Branch Moody, T Jake Liang, Richard S Blumberg. (2012) Hepatitis B virus–induced lipid alterations contribute to natural killer T cell–dependent protective immunity. Nature Medicine 18:7, 1060-1068
    

93. 93

    Xiaopan Wu, Zhenhui Xin, Xilin Zhu, Liping Pan, Zhuo Li, Hui Li, Ying Liu. (2012) Polymorphisms in ADAR1 gene affect response to interferon alpha based therapy for chronic hepatitis B in Han Chinese. Antiviral Research 94:3, 272-275
    

94. 94

    Han Hee Ryu, Eun Young Lee, Kichul Shin, In Ah Choi, Yun Jong Lee, Bin Yoo, Min-Chan Park, Yong-Beom Park, Sang-Cheol Bae, Wan Hee Yoo, Sung Il Kim, Eun Bong Lee, Yeong Wook Song. (2012) Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases. Clinical Rheumatology 31:6, 931-936
    

95. 95

    O. A. Postnikova, S. V. Aidagulova, D. L. Nepomnyashchikh, Zh. V. Nokhrina, E. V. Vinogradova, Yu. Yu. Karavaeva. (2012) Ultrastructural and Stereological Study of the Liver in Chronic Mixed HCV + HBV Infection. Bulletin of Experimental Biology and Medicine
    

96. 96

    Fang He, En-Qiang Chen, Li Liu, Tao-You Zhou, Cong Liu, Xing Cheng, Feng-Jun Liu, Hong Tang. (2012) Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA. Liver International 32:5, 742-751
    

97. 97

    He-Bin Fan, Ya-Bin Guo, You-Fu Zhu, An-Shen Chen, Mu-Xiu Zhou, Zhi Li, Li-Tong Xu, Xiao-Ju Ma, Fu-Ming Yan. (2012) Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection. Hepatitis Monthly 12:5, 333-338
    

98. 98

    R.M. Martín Mateos, F. García-Alonso, V. Moreira Vicente. (2012) Hepatitis crónica por virus B. Historia natural y tratamiento. Medicine - Programa de Formación Médica Continuada Acreditado 11:9, 521-528
    

99. 99

    Elena Sandalova, Diletta Laccabue, Carolina Boni, Tsunamasa Watanabe, Anthony Tan, Ho Zi Zong, Carlo Ferrari, Antonio Bertoletti. (2012) Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. Gastroenterology
    

100. 100

     N. Gara, X. Zhao, M. T. Collins, W. H. Chong, D. E. Kleiner, T. Jake Liang, M. G. Ghany, J. H. Hoofnagle. (2012) Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Alimentary Pharmacology & Therapeuticsn/a-n/a
     

101. 101

     Swati Gupta, Abhinav Agarwal, Nishant Kumar Gupta, Gauravkant Saraogi, Himanshu Agrawal, G.P Agrawal. (2012) Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir. Drug Development and Industrial Pharmacy1-8
     

102. 102

     Hong Zhang, Yanfei Qi, Yanhua Ding, Juan Wang, Qingmei Li, Jingzhou Zhang, Yanfang Jiang, Xiumei Chi, Juan Li, Junqi Niu. (2012) Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus. Bioorganic & Medicinal Chemistry Letters 22:4, 1664-1669
     

103. 103

     Xiao-Ling Zhou, Gareth J. Sullivan, Pingnan Sun, In-Hyun Park. (2012) Humanized murine model for HBV and HCV using human induced pluripotent stem cells. Archives of Pharmacal Research 35:2, 261-269
     

104. 104

     T. N. Q. Pham, C. S. Coffin, N. D. Churchill, S. J. Urbanski, S. S. Lee, T. I. Michalak. (2012) Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. Journal of Viral Hepatitis 19:2, 103-111
     

105. 105

     Zhuanbo Luo, Lanjuan Li, Bing Ruan. (2012) Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. International Journal of Infectious Diseases 16:2, e82-e88
     

106. 106

     Mamun Al-Mahtab, Sheikh Mohammad Fazle Akbar, Salimur Rahman, Mohammad Kamal, Mohammad Sakirul Islam Khan. (2012) Biochemical, Virological, Immunological and Histopathological Features of 702 Incidentally Detected Chronic Hepatitis B Virus Carriers in Bangladesh. Digestion 86:1, 1-5
     

107. 107

     Rish K. Pai, Elizabeth M. Brunt. Cirrhosis and portal hypertension. In: Blumgart's Surgery of the Liver, Pancreas and Biliary Tract. Elsevier, 2012:1079-1091.
     

108. 108

     Tianxiang Chen, Dongli Song, Zhihui Min, Xiangdong Wang, Yu Gu, Bajin Wei, Jia Yao, Kangjie Chen, Zhijun Jiang, Haiyang Xie, Lin Zhou, Shusen Zheng. (2012) Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma. Journal of Translational Medicine 10:1, 14
     

109. 109

     Eiji Tanaka, Yukitomo Urata. (2012) Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatology Researchno-no
     

110. 110

     Hee Bok Chae, Mee Jin Kim, Eui Geun Seo, Yong Hyeok Choi, Hee Seung Lee, Joung Ho Han, Soon Man Yoon, Seon Mee Park, Sei Jin Youn. (2012) High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. The Korean Journal of Hepatology 18:1, 75
     

111. 111

     In Sung Kim, Jun Il Mun, Jee Hoon Koo, Chang Jun Kang, Jean Kyung Bak, Jae Yoeun Cheong, Sung Won Cho. (2012) Entecavir Therapy for Patients with Hepatitis B Virus-related Decompensated Cirrhosis. The Korean Journal of Gastroenterology 59:3, 224
     

112. 112

     Sang Soo Lee, Young-Sang Byoun, Sook-Hyang Jeong, Yeo Myung Kim, Ho Gil, Bo-Young Min, Mun Hyuk Seong, Eun Sun Jang, Jin-Wook Kim. (2012) Type and cause of liver disease in Korea: single-center experience, 2005-2010. Clinical and Molecular Hepatology 18:3, 309
     

113. 113

     Liang Xue-Song, Li Cheng-Zhong, Zhou Ying, Wan Mo-Bin. (2012) Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterology 12:1, 43
     

114. 114

     Bin Wu, Jinfang Shen, Huafeng Cheng. (2012) Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Services Research 12:1, 385
     

115. 115

     Yanhai Guo, Wei Kei, Xiaoying Lei, Yongnian Li, An Xiang, Yonglan Liu, Jinrong Zhao, Ju Zhang, Zhen Yan. (2012) Hepatitis B viral core protein disrupts human host gene expression by binding to promoter regions. BMC Genomics 13:1, 563
     

116. 116

     Jean-Michel Pawlotsky, John Mchutchison. Chronic Viral and Autoimmune Hepatitis. In: Goldman's Cecil Medicine. Elsevier, 2012:973-979.
     

117. 117

     Na Li, Qianqian Zhu, Zhu Li, Qunying Han, Guoyu Zhang, Jinghong Chen, Yi Lv, Fanfan Xing, Yanping Chen, Xiaoyan Zeng, Zhengwen Liu. (2012) IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Molecular Carcinogenesisn/a-n/a
     

118. 118

     Poupak Fallahi, Clodoveo Ferri, Silvia Martina Ferrari, Alda Corrado, Domenico Sansonno, Alessandro Antonelli. (2012) Cytokines and HCV-Related Disorders. Clinical and Developmental Immunology 2012, 1-10
     

119. 119

     Transfusion-Transmitted Diseases. In: Transfusion Medicine. Wiley-Blackwell, 2011:414-445.
     

120. 120

     Arturo Montineri, Luciano Nigro, Rosario La Rosa, Carmelo Iacobello, Licia Larocca, Elisa Cappello, Paolo Fabio Fiumara, Francesco Di Raimondo, Filippo Fatuzzo. (2011) Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: A clinical survey of 5 cases in Catania, Italy. Journal of Clinical Virology 52:4, 284-287
     

121. 121

     Olivier Lada, Tarik Asselah, Patrick Marcellin. (2011) Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. Current Hepatitis Reports 10:4, 244-254
     

122. 122

     M. Lereau, D. Gouas, S. Villar, A. Besaratina, A. Hautefeuille, P. Bertillon, G. Martel-Planche, A. Nogueira da Costa, S. Ortiz-Cuaran, O. Hantz, G. P. Pfeifer, P. Hainaut, I. Chemin. (2011) Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells. Journal of General Virology
     

123. 123

     Saifur Rahman, Zafar K. Khan, Pooja Jain. (2011) The Tug-of-War between Dendritic Cells and Human Chronic Viruses. International Reviews of Immunology 30:5-6, 341-365
     

124. 124

     Qunying Han, Shaoqiong Duan, Guoyu Zhang, Zhu Li, Na Li, Qianqian Zhu, Yi Lv, Jinghong Chen, Zhengwen Liu. (2011) Associations between cytotoxic T lymphocyte-associated antigen-4 polymorphisms and serum tumor necrosis factor-α and interferon-γ levels in patients with chronic hepatitis B virus infection. Inflammation Research 60:11, 1071-1078
     

125. 125

     Emmet B. Keeffe. (2011) Access to Care and Optimal Treatment of Chronic Hepatitis B in Asian Americans: An Evolving Agenda. Digestive Diseases and Sciences 56:11, 3106-3108
     

126. 126

     Lucia Taramasso, Patrizia Caligiuri, Antonio Di Biagio, Bianca Bruzzone, Raffaella Rosso, Giancarlo Icardi, Claudio Viscoli. (2011) Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. Journal of Medical Virology 83:11, 1905-1908
     

127. 127

     Xiao-Ben Pan, Hui Ma, Qian Jin, Lai Wei. (2011) Characterization of microRNA expression profiles associated with hepatitis B virus replication and clearance in vivo and in vitro. Journal of Gastroenterology and Hepatologyno-no
     

128. 128

     Jianing Wang, Uma S. Singh, Ravindra K. Rawal, Massaya Sugiyama, Jakyung Yoo, Ashok K. Jha, Melissa Scroggin, Zhuhui Huang, Michael G. Murray, Rajgopal Govindarajan, Yasuhito Tanaka, Brent Korba, Chung K. Chu. (2011) Antiviral activity of novel 2′-fluoro-6′-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. Bioorganic & Medicinal Chemistry Letters 21:21, 6328-6331
     

129. 129

     W. S. Ayoub, E. B. Keeffe. (2011) Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics 34:10, 1145-1158
     

130. 130

     Spilios Manolakopoulos, Athanasia Striki, Melanie Deutsch, Maria Mela, Ioannis Ketikoglou, Dimitrios Tzourmakliotis, Emanuel K. Manesis, George V. Papatheodoridis. (2011) Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver International 31:10, 1525-1532
     

131. 131

     Wei-Wu Shi, Aifen Lin, Dan-Ping Xu, Wei-Guang Bao, Jian-Gang Zhang, Shi-Yong Chen, Jun Li, Wei-Hua Yan. (2011) Plasma soluble human leukocyte antigen-G expression is a potential clinical biomarker in patients with hepatitis B virus infection. Human Immunology 72:11, 1068-1073
     

132. 132

     M. L. Borresen, A. Koch, R. J. Biggar, M. Andersson, J. Wohlfahrt, K. Ladefoged, M. Melbye. (2011) Hepatocellular Carcinoma and Other Liver Disease Among Greenlanders Chronically Infected with Hepatitis B Virus: A Population-Based Study. JNCI Journal of the National Cancer Institute
     

133. 133

     S. Togo, M. Arai, A. Tawada, T. Chiba, T. Kanda, K. Fujiwara, F. Imazeki, O. Yokosuka. (2011) Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B. Journal of Viral Hepatitis 18:10, e508-e515
     

134. 134

     Sara Cmet, Carlo Fabris, Giovanna Fattovich, Edmondo Falleti, Davide Bitetto, Annarosa Cussigh, Elisabetta Fontanini, Ezio Fornasiere, Mario Pirisi, Pierluigi Toniutto. (2011) Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. Clinical & Experimental Immunologyno-no
     

135. 135

     Sarah Kutscher, Tanja Bauer, Claudia Dembek, Martin Sprinzl, Ulrike Protzer. (2011) Design of therapeutic vaccines: hepatitis B as an example. Microbial Biotechnologyno-no
     

136. 136

     Zheng Zhang, Ji-Yuan Zhang, Li-Feng Wang, Fu-Sheng Wang. (2011) Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatologyno-no
     

137. 137

     Melanie A. Mallory, Sam R. Page, David R. Hillyard. (2011) Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. Journal of Virological Methods 177:1, 31-37
     

138. 138

     A. Ong, V. W.-S. Wong, G. L.-H. Wong, H.-Y. Chan, C.-H. Tse, H. L.-Y. Chan. (2011) Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Alimentary Pharmacology & Therapeutics 34:8, 972-981
     

139. 139

     D. Li, J. Liu, F. Kang, W. Guan, X. Gao, Y. Wang, D. Sun. (2011) Core-APOBEC3C chimerical protein inhibits hepatitis B virus replication. Journal of Biochemistry 150:4, 371-374
     

140. 140

     Lifeng Liu, Jin Li, Jinjian Yao, Jinling Yu, Jinliang Zhang, Qin Ning, Zirong Wen, Daguo Yang, Yongwen He, Xinjuan Kong, Qilong Song, Man Chen, Hong Yang, Qing Liu, Senlin Li, Jusheng Lin. (2011) A Genome-Wide Association Study with DNA Pooling Identifies the Variant rs11866328 in the GRIN2A Gene That Affects Disease Progression of Chronic HBV Infection. Viral Immunology 24:5, 397-402
     

141. 141

     Pin-Yu Perera, Jack H. Lichy, Thomas A. Waldmann, Liyanage P. Perera. (2011) The role of interleukin-15 in inflammation and immune responses to infection: Implications for its therapeutic use. Microbes and Infection
     

142. 142

     Samuel E Moses, ZiYi Lim, Mark A Zuckerman. (2011) Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 9:10, 891-899
     

143. 143

     Rajesh Kumar, Vikas Pahal, Jasbir Singh. (2011) Prevalence of Genotype D and Precore/Core Promoter Mutations in Hepatitis B Virus-infected Population of North India. Journal of Clinical and Experimental Hepatology 1:2, 73-76
     

144. 144

     Lok-Beng Koay, I-Che Feng, Ming-Jen Sheu, Hsing-Tao Kuo, Chin-Yih Lin, Jyh-Jou Chen, Shih-Ling Wang, Ling-Yu Tang, Sun-Lung Tsai. (2011) Hepatitis B virus (HBV) core antigen-specific regulatory T cells confer sustained remission to anti-HBV therapy in chronic hepatitis B with acute exacerbation. Human Immunology 72:9, 687-698
     

145. 145

     Dimitra Topka, Labros Theodosopoulos, Ioannis Elefsiniotis, George Saroglou, Hero Brokalaki. (2011) PREVALENCE OF HEPATITIS B IN HAEMODIALYSIS NURSING STAFF IN ATHENS. Journal of Renal Careno-no
     

146. 146

     Wei Wang, Yang Liu, Xiangyang Zu, Rui Jin, Gengfu Xiao. (2011) Blocking peptides against HBV: PreS1 protein selected from a phage display library. Biochemical and Biophysical Research Communications 412:4, 633-637
     

147. 147

     Shi-Yie Cheng, Chao-Min Wang, Yuan-Man Hsu, Tsurng-Juhn Huang, Shen-Chieh Chou, En-Hung Lin, Chang-Hung Chou. (2011) Oleanane-Type Triterpenoids from the Leaves and Twigs of Fatsia polycarpa. Journal of Natural Products 74:8, 1744-1750
     

148. 148

     Cameron J. Browne, Sergei S. Pilyugin. (2011) Periodic Multidrug Therapy in a Within-Host Virus Model. Bulletin of Mathematical Biology
     

149. 149

     Zhengyuan Shi, Kaishun Bi, Yang Li, Xin Hu, Kexin Li, Ping Gong, Xiaohui Chen. (2011) Determination of imidol hydrochloride in human plasma and urine by high-performance liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetic study. Biomedical Chromatographyn/a-n/a
     

150. 150

     Yuqin Yao, Jiong Li, Zejun Lu, Aiping Tong, Wei Wang, Xiaolan Su, Yan Zhou, Bo Mu, Shijie Zhou, Xiaoan Li, Lijuan Chen, Lantu Gou, Hongbing Song, Jinliang Yang, Yuquan Wei. (2011) Proteomic analysis of the interleukin-4 (IL-4) response in hepatitis B virus-positive human hepatocelluar carcinoma cell line HepG2.2.15. ELECTROPHORESIS 32:15, 2004-2012
     

151. 151

     Hui-fang Chai, Xin-xia Liang, Lin Li, Chun-shen Zhao, Ping Gong, Zhong-jie Liang, Wei-liang Zhu, Hua-liang Jiang, Cheng Luo. (2011) Identification of novel 5-hydroxy-1H-indole-3-carboxylates with anti-HBV activities based on 3D QSAR studies. Journal of Molecular Modeling 17:8, 1831-1840
     

152. 152

     Lifeng Liu, Jinjian Yao, Jin Li, Jinliang Zhang, Jinling Yu, Xiaorui Jiang, Shuzhen Sun, Qing Liu, Ying Chang, Yongwen He, Jusheng Lin. (2011) Effects of variant rs346473 in ARHGAP24 gene on disease progression of HBV infection in han Chinese population. Journal of Huazhong University of Science and Technology [Medical Sciences] 31:4, 482-487
     

153. 153

     T. Pollicino, C. Saitta, G. Raimondo. (2011) Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 32:8, 1122-1132
     

154. 154

     Ramazan Idilman, Mutlu Arat. (2011) Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Review of Anti-infective Therapy 9:8, 641-652
     

155. 155

     Bouchra Kitab, Abdellah Essaid El Feydi, Rajaa Afifi, Omar Derdabi, Younes Cherradi, Mustapha Benazzouz, Khadija Rebbani, Ikram Brahim, Hanane Salih Alj, Fabien Zoulim, Christian Trepo, Isabelle Chemin, Sayeh Ezzikouri, Soumaya Benjelloun. (2011) Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. Journal of Infection 63:1, 66-75
     

156. 156

     Yaxin Wang, Bo Gao, Wei Xu, Sidong Xiong. (2011) BRG1 is indispensable for IFN-γ-induced TRIM22 expression, which is dependent on the recruitment of IRF-1. Biochemical and Biophysical Research Communications 410:3, 549-554
     

157. 157

     Adam J. Gehring, Shao-An Xue, Zi Zong Ho, Denise Teoh, Christiane Ruedl, Adeline Chia, Sarene Koh, Seng Gee Lim, Mala K. Maini, Hans Stauss, Antonio Bertoletti. (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology 55:1, 103-110
     

158. 158

     Chang Young Son, Seung Up Kim, Woong Kyu Han, Gi Hong Choi, Hana Park, Seung Choul Yang, Jin Sub Choi, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Kwang-Hyub Han. (2011) Normal liver elasticity values using acoustic radiation force impulse (ARFI) imaging: a prospective study in healthy living liver and kidney donors. Journal of Gastroenterology and Hepatologyno-no
     

159. 159

     Ramazan Idilman, Yusuf Bozkus, Guldane Seval, Dilsa Mizrak, Kubilay Cinar, Yusuf Ustun, Mehmet Bektas, Mutlu Arat, Hakan Akbulut, Beyza Doganay, Ali Ozden. (2011) Lymphoproliferative disorders in individuals with chronic hepatitis b and C in the Turkish population. Journal of Medical Virology 83:6, 974-980
     

160. 160

     Zhen Sun, Wenqing Xiang, Yajuan Guo, Zhi Chen, Wei Liu, Daru Lu. (2011) Inhibition of hepatitis B virus (HBV) by LNA-mediated nuclear interference with HBV DNA transcription. Biochemical and Biophysical Research Communications 409:3, 430-435
     

161. 161

     Qian Gong, Shu Chen, Jinjun Guo, Hang Sun, Guoxing Zheng, Qi Liu, Hong Ren, Song He. (2011) Chromosome Remodeling Related to Hepatitis B Virus Replication in HepG2 Cells. DNA and Cell Biology 30:6, 347-354
     

162. 162

     Marie-Louise Michel, Qiang Deng, Maryline Mancini-Bourgine. (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges. Journal of Hepatology 54:6, 1286-1296
     

163. 163

     Pattaratida Sa-nguanmoo, Yasuhito Tanaka, Parntep Ratanakorn, Masaya Sugiyama, Shuko Murakami, Sunchai Payungporn, Angkana Sommanustweechai, Masashi Mizokami, Yong Poovorawan. (2011) Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes. Virus Research 158:1-2, 209-215
     

164. 164

     C-C Chen, C-M Chang, C-P Sun, C-P Yu, P-Y Wu, K-S Jeng, C-P Hu, P-J Chen, J-C Wu, C-h Shih, M E Gershwin, M-H Tao. (2011) Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Therapy
     

165. 165

     Xiao-Qin Chen, Jie-Wen Peng, Gui-Nan Lin, Mei Li, Zhong-Jun Xia. (2011) The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Medical Oncology
     

166. 166

     Xian Hao, Xin Shang, Jiazhen Wu, Yuping Shan, Mingjun Cai, Junguang Jiang, Zhong Huang, Zhiyong Tang, Hongda Wang. (2011) Single-Particle Tracking of Hepatitis B Virus-like Vesicle Entry into Cells. Small 7:9, 1212-1218
     

167. 167

     M. Veroux, D. Corona, B. Ekser, A. Giaquinta, T. Tallarita, C. De Martino, F. Gentile, C. Virgilio, M. Gagliano, P. Fiamingo, P. Veroux. (2011) Kidney Transplantation From Hepatitis B Virus Core Antibody–Positive Donors: Prophylaxis With Hepatitis B Immunoglobulin. Transplantation Proceedings 43:4, 967-970
     

168. 168

     Sheng C. Lou, Sandra K. Pearce, Teresa X. Lukaszewska, Russell E. Taylor, Gregg T. Williams, Thomas P. Leary. (2011) An improved Abbott ARCHITECT® assay for the detection of hepatitis B virus surface antigen (HBsAg). Journal of Clinical Virology 51:1, 59-63
     

169. 169

     Wenjin Xi, Yejia Hu, Yugang Liu, Jiao Zhang, Lei Wang, Yunwei Lou, Zhonghua Qu, Jian Cui, Guizhong Zhang, Xiaohong Liang, Chunhong Ma, Chengjiang Gao, Youhai Chen, Suxia Liu. (2011) Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Molecular Immunology 48:9-10, 1203-1208
     

170. 170

     María Mora González López Ledesma, Omar Galdame, Belén Bouzas, Luciana Tadey, Beatriz Livellara, Silvina Giuliano, Marcela Viaut, Silvia Paz, Hugo Fainboim, Adrian Gadano, Rodolfo Campos, Diego Flichman. (2011) Characterization of the basal core promoter and precore regions in anti-HBe-positive inactive carriers of hepatitis B virus. International Journal of Infectious Diseases 15:5, e314-e320
     

171. 171

     Anna S. F. Lok. Hepatitis B. In: Sherlock's Diseases of the Liver and Biliary System. Wiley-Blackwell, 2011:367-392.
     

172. 172

     Rui Nie, Lei Jin, Hanwang Zhang, Bei Xu, Wen Chen, Guijin Zhu. (2011) Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. Fertility and Sterility 95:5, 1667-1671
     

173. 173

     William H. James. (2011) Further support for a hypothesis on the reported offspring sex ratios of hepatitis B carriers. Journal of Theoretical Biology 274:1, 183-184
     

174. 174

     Matthew B Carroll. (2011) The impact of biologic response modifiers on hepatitis B virus infection. Expert Opinion on Biological Therapy 11:4, 533-544
     

175. 175

     Pin-Nan Cheng, Wen-Chun Liu, Hung-Wen Tsai, I-Chin Wu, Ting-Tsung Chang, Kung-Chia Young. (2011) Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. Journal of Medical Virology 83:4, 602-607
     

176. 176

     Dong Chen, Yajing Liu, Shulan Zhang, Dexiang Guo, Chunhong Liu, Sai Li, Ping Gong. (2011) Synthesis and in-vitro Anti-hepatitis B Virus Activity of Ethyl 6-Bromo-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylates. Archiv der Pharmazie 344:3, 158-164
     

177. 177

     Jean Publicover, Amanda Goodsell, Stephen Nishimura, Silvia Vilarinho, Zhi-en Wang, Lia Avanesyan, Rosanne Spolski, Warren J. Leonard, Stewart Cooper, Jody L. Baron. (2011) IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. Journal of Clinical Investigation 121:3, 1154-1162
     

178. 178

     S. M. F. Akbar, N. Horiike, S. Chen, K. Michitaka, M. Abe, Y. Hiasa, B. Matsuura, M. Onji. (2011) Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells. Journal of Viral Hepatitis 18:3, 200-205
     

179. 179

     Jinjong Myoung, Don Ganem. (2011) Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. Journal of Clinical Investigation 121:3, 1130-1140
     

180. 180

     M. John von Freyend, A. Untergasser, S. Arzberger, H. Oberwinkler, U. Drebber, P. Schirmacher, U. Protzer. (2011) Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. Journal of Viral Hepatitis 18:3, 216-226
     

181. 181

     Masaaki Watanabe, Akitaka Shibuya, Yuhko Tsunoda, Mikio Danbara, Ryuji Ishii, Manabu Ohsaka, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Ryouichi Horie, Masaaki Higashihara, Wasaburo Koizumi. (2011) Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver International 31:3, 340-347
     

182. 182

     Iddo Bar-Yishay, Yosef Shaul, Amir Shlomai. (2011) Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver International 31:3, 282-290
     

183. 183

     J. Inoue, Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, Y. Yamagiwa, M. Shiina, Y. Kondo, E. Kakazu, K. Tamai, N. Obara, T. Iwasaki, T. Shimosegawa. (2011) Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. Journal of Viral Hepatitis 18:3, 206-215
     

184. 184

     Yukitomo Urata, Ryoko Uesato, Dai Tanaka, Kenji Kowatari, Taisuke Nitobe, Yoshihide Nakamura, Shigeru Motomura. (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 21:1, 16-23
     

185. 185

     Ray M. Merrill, Bradley D. Hunter. (2011) Seroprevalence of markers for hepatitis B viral infection. International Journal of Infectious Diseases 15:2, e78-e121
     

186. 186

     Yen-Hsuan Ni. (2011) Natural history of hepatitis B virus infection: pediatric perspective. Journal of Gastroenterology 46:1, 1-8
     

187. 187

     Yun-Jian Sheng, Jun-Ying Liu, Shi-Wen Tong, Huai-Dong Hu, Da-Zhi Zhang, Peng Hu, Hong Ren. (2011) Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virology Journal 8:1, 393
     

188. 188

     Rami Moucari, Patrick Marcellin. (2011) Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver International 31, 122-128
     

189. 189

     Jie Chen, Zhenglun Liang, Fengmin Lu, Xin Fang, Shuang Liu, Ying Zeng, Fengcai Zhu, Xiangmei Chen, Tao Shen, Jie Li, Hui Zhuang. (2011) Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine 29:4, 706-711
     

190. 190

     Stephanos J. Hadziyannis. (2011) Milestones and perspectives in viral hepatitis B. Liver International 31, 129-134
     

191. 191

     Mirella Fraquelli, Federica Branchi. (2011) The role of transient elastography in patients with hepatitis B viral disease. Digestive and Liver Disease 43, S25-S31
     

192. 192

     Jin-Gang Gu, Cheng-liang Zhu, Duo-zhi Cheng, Yan Xie, Fang Liu, Xin Zhou. (2011) Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids in Health and Disease 10:1, 154
     

193. 193

     Silvana C. Faria, Sameer M. Mazhar, Michael R. Peterson, Masoud Shiehmorteza, Claude B. Sirlin. Hepatitis. In: Abdominal Imaging. Elsevier, 2011:641-653.
     

194. 194

     Zheng Zhang, Shuye Zhang, Zhengsheng Zou, Jianfei Shi, Juanjuan Zhao, Rong Fan, Enqiang Qin, Baosen Li, Zhiwei Li, Xiangsheng Xu, Junliang Fu, Jiyuan Zhang, Bin Gao, Zhigang Tian, Fu-Sheng Wang. (2011) Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53:1, 73-85
     

195. 195

     Fan Zhang, Simin Yao, Jing Yuan, Mingxia Zhang, Qing He, Guilin Yang, Zhiliang Gao, Hong Liu, Xinchun Chen, Boping Zhou. (2011) Elevated IL-6 Receptor Expression on CD4+ T Cells contributes to the increased Th17 Responses in patients with Chronic Hepatitis B. Virology Journal 8:1, 270
     

196. 196

     Xin Yao, Xuan-yi Wang, Chao Zhao, Shu-hui Sun, Zhe-feng Meng, Ji-ming Zhang, Jian-qing Xu, You-hua Xie, Zheng-hong Yuan, Yu-mei Wen. (2011) Transcriptional analysis of immune-related genes in dendritic cells from hepatitis B surface antigen (HBsAg)-positive transgenic mice and regulation of Fc gamma receptor IIB by HBsAg-anti-HBs complex. Journal of Medical Virology 83:1, 78-87
     

197. 197

     Michael Costello, Linda M. Sabatini, Margaret Yungbluth. Viral Infections. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. Elsevier, 2011:1037-1064.
     

198. 198

     Paulina Cybulska, Andy Ni, Carolina Jimenez-Rivera. (2011) Viral Hepatitis: Retrospective Review in a Canadian Pediatric Hospital. ISRN Pediatrics 2011, 1-4
     

199. 199

     G. Benoist, I. Ollivier, B. Viaris de Lesegno, S. Gouarin, M. Herlicoviez. Autres infections virales et grossesse. In: Le diagnostic prénatal en pratique. Elsevier, 2011:361-372.
     

200. 200

     Joanne Mann, Mick Roberts. (2011) Modelling the epidemiology of hepatitis B in New Zealand. Journal of Theoretical Biology 269:1, 266-272
     

201. 201

     Yanfang Zhao, Yajing Liu, Dong Chen, Zengquan Wei, Wenzhao Liu, Ping Gong. (2010) Synthesis and biological evaluation of 1H-benzimidazol-5-ols as potent HBV inhibitors. Bioorganic & Medicinal Chemistry Letters 20:24, 7230-7233
     

202. 202

     John W. Ayers, Hee-Soon Juon, Sunmin Lee, Eunmi Park. (2010) Hepatitis B Vaccination Prevalence and its Predictors Among Asian, Pacific Islander, Native American, and Multiracial Adults in the National Health and Nutrition Examination Survey. Journal of Immigrant and Minority Health 12:6, 847-852
     

203. 203

     Fan Wang, Haiyan Zhou, Xiumei Xia, Qian Sun, Ying Wang, Bin Cheng. (2010) Activated Notch signaling is required for hepatitis B virus X protein to promote proliferation and survival of human hepatic cells. Cancer Letters 298:1, 64-73
     

204. 204

     Zhinong Yin, Chenling Xiong, Yongguang Wang, Xin Zhou, Sheng-Kai Yan. (2010) Investigation of the relationship between apolipoprotein E gene polymorphisms and hepatitis B virus infection in northern China. Clinical Chemistry and Laboratory Medicine 48:12, 1803-1807
     

205. 205

     Mohamed M.S. Farag, Birgit Hoyler, Jens Encke, Wolfgang Stremmel, Kilian Weigand. (2010) Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice. Vaccine 29:2, 200-206
     

206. 206

     Karsten Wursthorn, Mechthild Jung, Antonio Riva, Zachary D. Goodman, Patricia Lopez, Weibin Bao, Michael P. Manns, Heiner Wedemeyer, Nikolai V. Naoumov. (2010) Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52:5, 1611-1620
     

207. 207

     Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada. (2010) HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver International 30:10, 1461-1470
     

208. 208

     Ke Wang, Hongli Liu, Yingli He, Tianyan Chen, Yuan Yang, Yinghua Niu, Hongmei Chen, Yunru Chen, Jinfeng Liu, Feng Ye, Shumei Lin, Yingren Zhao. (2010) Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Human Immunology 71:10, 950-956
     

209. 209

     Herbert A. Perkins, Michael P. Busch. (2010) Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 50:10, 2080-2099
     

210. 210

     Ambujam N Kapoor, Prathap Tharyan, Lalit Kant, Vinohar Balraj, Ian Shemilt, Ambujam N Kapoor. Combined DTP-HBV vaccine versus separately administered DTP and HBV vaccines for primary prevention of diphtheria, tetanus, pertussis, and hepatitis B. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2010.
     

211. 211

     Hui Ma, Rui-feng Yang, Lai Wei. (2010) Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. Journal of Gastroenterology and Hepatology 25:9, 1498-1506
     

212. 212

     Matthew B. Carroll, Michael A. Forgione. (2010) Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clinical Rheumatology 29:9, 1021-1029
     

213. 213

     Pisit Tangkijvanich, Pattaratida Sa-nguanmoo, Varocha Mahachai, Apiradee Theamboonlers, Yong Poovorawan. (2010) A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma. Hepatology International 4:3, 577-584
     

214. 214

     Inmaculada Rivas, Elisenda Martinez, Arantza Sanvisens, Ferran Bolao, Jordi Tor, Marta Torrens, Ramon Pujol, Daniel Fuster, Celestino Rey-Joly, Álvaro Muñoz, Roberto Muga. (2010) Hepatitis B virus serum profiles in injection drug users and rates of immunization over time in Barcelona: 1987–2006. Drug and Alcohol Dependence 110:3, 234-239
     

215. 215

     Bin Sun, Yanjun Wang, Qinghua Meng, Daojie Liu, Peiling Dong, Huiguo Ding, Hao Wu. (2010) Dynamics of memory T cells during treatment with interferon-alpha in patients with chronic hepatitis B. Hepatology Research 40:8, 806-812
     

216. 216

     Masaaki Watanabe, Akitaka Shibuya, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Wasaburo Koizumi. (2010) Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients. European Journal of Internal Medicine 21:4, 333-337
     

217. 217

     Pattaratida Sa-nguanmoo, Pisit Tangkijvanich, Nutchanart Thawornsuk, Preeyaporn Vichaiwattana, Kesmanee Prianantathavorn, Apiradee Theamboonlers, Yasuhito Tanaka, Yong Poovorawan. (2010) Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. Journal of Medical Virology 82:8, 1341-1349
     

218. 218

     Mei Hwei Chang. (2010) Hepatitis B Vaccination: Disease and Cancer Prevention—A Taiwanese Experience. Clinics in Liver Disease 14:3, 521-530
     

219. 219

     Mamun Al-Mahtab, Salimur Rahman, Sheikh Mohammad Fazle Akbar, Mohammad Kamal, Mohammad Sakirul Islam Khan. (2010) Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. Journal of Medical Virology 82:8, 1350-1354
     

220. 220

     You-hua Xie, Ran Hong, Wei Liu, Jing Liu, Jian-wei Zhai. (2010) Development of novel therapeutics for chronic hepatitis B. Virologica Sinica 25:4, 294-300
     

221. 221

     S. Yu, J. Chen, M. Wu, H. Chen, N. Kato, Z. Yuan. (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKK  and DDX3. Journal of General Virology 91:8, 2080-2090
     

222. 222

     Sergei N Shchelkunov, Galina A Shchelkunova. (2010) Plant-based vaccines against human hepatitis B virus. Expert Review of Vaccines 9:8, 947-955
     

223. 223

     Ashoke Sharon, Ashok K. Jha, Chung K. Chu. Clevudine, to Treat Hepatitis B Viral Infection. In: Analogue-Based Drug Discovery II. Wiley-VCH Verlag GmbH & Co. KGaA, 2010:383-408.
     

224. 224

     Kazuto Tajiri, Tatsuhiko Ozawa, Aishun Jin, Yoshiharu Tokimitsu, Masami Minemura, Hiroyuki Kishi, Toshiro Sugiyama, Atsushi Muraguchi. (2010) Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine. Antiviral Research 87:1, 40-49
     

225. 225

     Bin Wu, Te Li, Huafeng Chen, Jinfang Shen. (2010) Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health 13:5, 592-600
     

226. 226

     Khalid Mumtaz, Sarah Haroon Khan, Owais Iqbal Bhatti, Saeed Hamid, Wasim Jafri, Khalid Mumtaz. Interferon alpha for chronic hepatitis B. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2010.
     

227. 227

     Melissa Kennedy, Sophoclis P Alexopoulos. (2010) Hepatitis B virus infection and liver transplantation. Current Opinion in Organ Transplantation 15:3, 310-315
     

228. 228

     Mamun Al-Mahtab, Salimur Rahman, Sheikh Mohammad Fazle Akbar, Sakirul Islam Khan, Helal Uddin, Fazal Karim, Faroque Ahmed. (2010) Combination Therapy with Antiviral Drugs and Hepatitis B Vaccine in Incidentally-Detected and Asymptomatic Chronic Hepatitis Virus B Carriers at Bangladesh. Viral Immunology 23:3, 335-338
     

229. 229

     Nicole E. Pagliaccetti, Esther N. Chu, Christopher R. Bolen, Steven H. Kleinstein, Michael D. Robek. (2010) Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 401:2, 197-206
     

230. 230

     M. Abdou Chekaraou, S. Brichler, W. Mansour, F. Le Gal, A. Garba, P. Deny, E. Gordien. (2010) A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. Journal of General Virology 91:6, 1609-1620
     

231. 231

     Alajos Pár. (2010) Hepatitis B-vírus- (HBV-) infekció és hepatocarcinogenesis. Orvosi Hetilap 151:26, 1045-1053
     

232. 232

     Dianxing Sun, Christine Rösler, Karin Kidd-Ljunggren, Michael Nassal. (2010) Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. Journal of Hepatology 52:6, 817-826
     

233. 233

     James Fung, Ching-Lung Lai, Man-Fung Yuen. (2010) Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Review of Anti-infective Therapy 8:6, 717-726
     

234. 234

     Maya Mouler Rechtman, Ofir Har-Noy, Iddo Bar-Yishay, Sigal Fishman, Yaarit Adamovich, Yosef Shaul, Zamir Halpern, Amir Shlomai. (2010) Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1α. FEBS Letters 584:11, 2485-2490
     

235. 235

     Florence Bayard, Silvina Malmassari, Qiang Deng, Yu-Chun Lone, Marie-Louise Michel. (2010) Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo. Vaccine 28:22, 3818-3826
     

236. 236

     Dorit Cohen, Yaarit Adamovich, Nina Reuven, Yosef Shaul. (2010) Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology 51:5, 1538-1546
     

237. 237

     S. Louisirirotchanakul, K. Khupulsup, S. Akraekthalin, K.P. Chan, S. Saw, T.C. Aw, D.-H. Cho, M.-G. Shin, J. Lim. (2010) Comparison of the technical and clinical performance of the Elecsys® HBsAg II assay with the Architect®, AxSym®, and Advia® Centaur HBsAg screening assays. Journal of Medical Virology 82:5, 755-762
     

238. 238

     Markus Peck-Radosavljevic, Johann Deutsch, Peter Ferenci, Ivo Graziadei, Harald Hofer, Heidemarie Holzmann, Wolf-Dietrich Huber, Herman Laferl, Andreas Maieron, Rudolf Stauber, Wolfgang Vogel. (2010) 4. Österreichischer Konsensusbericht zur Diagnose und Therapie der Hepatitis B 2009. Wiener klinische Wochenschrift 122:9-10, 280-302
     

239. 239

     Xiaohua Chen, Jinglan Lai, Qingchun Pan, Zhenghao Tang, Yongsheng Yu, Guoqing Zang. (2010) The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice. Vaccine 28:23, 3913-3919
     

240. 240

     CHIEN-YI CHEN, MEI-HWEI CHANG. (2010) HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. Fetal and Maternal Medicine Review 21:02, 89-113
     

241. 241

     Sarah Hews, Steffen Eikenberry, John D. Nagy, Yang Kuang. (2010) Rich dynamics of a hepatitis B viral infection model with logistic hepatocyte growth. Journal of Mathematical Biology 60:4, 573-590
     

242. 242

     Kazuhiko Hayashi, Yoshiaki Katano, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Kentaro Yoshioka, Motoyoshi Yano, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2010) Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains. Journal of Gastroenterology and Hepatology 25:4, 745-749
     

243. 243

     Christine Neuveut, Yu Wei, Marie Annick Buendia. (2010) Mechanisms of HBV-related hepatocarcinogenesis. Journal of Hepatology 52:4, 594-604
     

244. 244

     T. Han, H. Liu, Z.L. Yu, J. Li, L. Wang, S.X. Xiao, Y. Li, M.L. Yu. (2010) Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure. Journal of Viral Hepatitis 17, 18-23
     

245. 245

     Haeok Lee, Wanju Park, Jin Hyang Yang, Kwang Soo You. (2010) Management of Hepatitis B Virus Infection. Gastroenterology Nursing 33:2, 120-126
     

246. 246

     MATTHEW EDEY, KATHERINE BARRACLOUGH, DAVID W JOHNSON. (2010) Review article: Hepatitis B and dialysis. Nephrology 15:2, 137-145
     

247. 247

     S. W. Cho, K. H. Koh, J. Y. Cheong, M. H. Lee, S. P. Hong, W. D. Yoo, S.-O. Kim. (2010) Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. Journal of Viral Hepatitis 17:3, 171-177
     

248. 248

     L. J. Liu, J. H. Wang, S. C. Du, J. H. Tian, R. F. Yang, L. Wei. (2010) rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B. Journal of Viral Hepatitis 17, 66-72
     

249. 249

     Pisit Tangkijvanich, Piyawat Komolmit, Varocha Mahachai, Pattaratida Sa-nguanmoo, Apiradee Theamboonlers, Yong Poovorawan. (2010) Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatology Research 40:3, 269-277
     

250. 250

     H. H. Zhang, M. H. Mei, R. Fei, F. Liu, J. H. Wang, W. J. Liao, L. L. Qin, L. Wei, H. S. Chen. (2010) Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. Journal of Viral Hepatitis 17, 34-43
     

251. 251

     Kazuyoshi Ohkawa, Tetsuo Takehara, Hisashi Ishida, Takahiro Kodama, Satoshi Shimizu, Hayato Hikita, Masashi Yamamoto, Keisuke Kohga, Akira Sasakawa, Akio Uemura, Ryotaro Sakamori, Shinjiro Yamaguchi, Wei Li, Atsushi Hosui, Takuya Miyagi, Tomohide Tatsumi, Kazuhiro Katayama, Norio Hayashi. (2010) Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion. Biochemical and Biophysical Research Communications 394:1, 87-93
     

252. 252

     Pierluigi Toniutto, Giovanna Fattovich, Carlo Fabris, Rosalba Minisini, Michela Burlone, Cecilia Pravadelli, Laura Peraro, Edmondo Falleti, Francesca Caldera, Davide Bitetto, Mario Pirisi. (2010) Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B. Journal of Medical Virology 82:2, 224-331
     

253. 253

     Tetsuya Hosaka, Fumitaka Suzuki, Masahiro Kobayashi, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yastuji, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yuzo Miyakawa, Hiromitsu Kumada. (2010) Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatology Research 40:2, 145-152
     

254. 254

     T. L. Kieffer, A. D. Kwong, G. R. Picchio. (2010) Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). Journal of Antimicrobial Chemotherapy 65:2, 202-212
     

255. 255

     A. Tamori, M. Enomoto, S. Kobayashi, S. Iwai, H. Morikawa, H. Sakaguchi, D. Habu, S. Shiomi, Y. Imanishi, N. Kawada. (2010) Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. Journal of Viral Hepatitis 17:2, 123-129
     

256. 256

     Si Nafa Si Ahmed, Marie Ecochard, Fabien Zoulim. (2010) End points of therapy in chronic hepatitis B. Expert Review of Gastroenterology & Hepatology 4:1, 37-49
     

257. 257

     Jia-Ming Chang, Kai-Ling Huang, Thomas Ta-Tung Yuan, Yiu-Kay Lai, Le-Mei Hung. (2010) The Anti-Hepatitis B Virus Activity of Boehmeria nivea Extract in HBV-Viremia SCID Mice. Evidence-Based Complementary and Alternative Medicine 7:2, 189-195
     

258. 258

     Simona Urbani, Francesco Fagnoni, Gabriele Missale, Massimo Franchini. (2010) The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clinical Chemistry and Laboratory Medicine 48:1, 23-29
     

259. 259

     K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, P. M. Girard. (2010) HIV/hepatitis B virus co-infection: current challenges and new strategies. Journal of Antimicrobial Chemotherapy 65:1, 10-17
     

260. 260

     Chao Zhao, Wei Zhang, Xiaochen Tian, Caiyun Fang, Haojie Lu, Zhenghong Yuan, Pengyuan Yang, Yumei Wen. (2010) Proteomic analysis of cell lines expressing small hepatitis B surface antigen revealed decreased glucose-regulated protein 78âkDa expression in association with higher susceptibility to apoptosis. Journal of Medical Virology 82:1, 14-22
     

261. 261

     U. Protzer, H. Abken. (2010) Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?. Hepatitis Research and Treatment 2010, 1-9
     

262. 262

     Tereza Holotnakova, Lucia Tylkova, Martina Takacova, Juraj Kopacek, Juraj Petrik, Silvia Pastorekova, Jaromir Pastorek. (2010) Role of the HBx oncoprotein in carbonic anhydrase 9 induction. Journal of Medical Virology 82:1, 32-40
     

263. 263

     Jay H. Lefkowitch. Chronic Hepatitis. In: Scheuer's Liver Biopsy Interpretation. Elsevier, 2010:133-161.
     

264. 264

     D.J. Hu, W.A. Bower, J.W. Ward. Viral Hepatitis. In: Atlas of Sexually Transmitted Diseases and AIDS. Elsevier, 2010:203-229.
     

265. 265

     Viral Hepatitis. In: Current Clinical Medicine. Elsevier, 2010:539-551.
     

266. 266

     Maimuna Mendy, Robert Walton. (2009) Molecular pathogenesis and early detection of hepatocellular carcinoma – Perspectives from West Africa. Cancer Letters 286:1, 44-51
     

267. 267

     Siba P. Raychaudhuri, Caroline T. Nguyen, Smriti K. Raychaudhuri, M. Eric Gershwin. (2009) Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmunity Reviews 9:2, 67-81
     

268. 268

     Amir Shlomai, Yoav Lubelsky, Ofir Har-Noy, Yosef Shaul. (2009) The “Trojan horse” model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector. Biochemical and Biophysical Research Communications 390:3, 619-623
     

269. 269

     I. Chemin, F. Zoulim. (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Letters 286:1, 52-59
     

270. 270

     Yuanyuan Lin, Xiaoming Cheng, Yuhu Song, Li Zhou, Peiyuan Li, Ying Chang, Leiming Xu, Jinjian Yao, Jusheng Lin. (2009) Construction and expression of hepatitis B virus vector encoding TC-tagged core protein. Frontiers of Medicine in China 3:4, 396-402
     

271. 271

     Geoffrey Dusheiko, Tabinda Burney. (2009) Current treatment of chronic HBV infection: A European perspective. Current Hepatitis Reports 8:4, 141-147
     

272. 272

     Ji-Dong Jia, Ma Hong, Lai Wei, Xin-Xin Zhang, Yuan-Li Mao, Lan-Lan Wang, Zhi-Liang Gao, Jin-Lin Hou, Jun Zhang. (2009) Multicentre evaluation of the Elecsys® hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays. Medical Microbiology and Immunology 198:4, 263-269
     

273. 273

     Pisit Tangkijvanich, Piyawat Komolmit, Varocha Mahachai, Pattaratida Sa-nguanmoo, Apiradee Theamboonlers, Yong Poovorawan. (2009) Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. Journal of Clinical Virology 46:2, 117-123
     

274. 274

     Jie-li Hu, Jing Cui, Xiao-yan Deng, Wen-lu Zhang, Qing-ling Li, Jin-jun Guo, Ai-zhong Zeng, Ai-long Huang. (2009) A new strategy for constructing in vitro replication-competent 1.3 copies of hepatitis B virus genome. Journal of Virological Methods 161:1, 63-69
     

275. 275

     Jian-Qi Lian, Xiao-Qin Wang, Ye Zhang, Chang-Xing Huang, Xue-Fan Bai. (2009) Correlation of Circulating TLR2/4 Expression with CD3 ⁺ /4 ⁺ /8 ⁺ T Cells and Treg cells in HBV-Related Liver Cirrhosis. Viral Immunology 22:5, 301-308
     

276. 276

     Tara N. Palmore, Neeral L. Shah, Rohit Loomba, Brian B. Borg, Uri Lopatin, Jordan J. Feld, Farooq Khokhar, Glen Lutchman, David E. Kleiner, Neal S. Young, Richard Childs, A. John Barrett, T. Jake Liang, Jay H. Hoofnagle, Theo Heller. (2009) Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. Clinical Gastroenterology and Hepatology 7:10, 1130-1137
     

277. 277

     Maria Buti, Max Brosa, Miguel A. Casado, Magdalena Rueda, Rafael Esteban. (2009) Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Journal of Hepatology 51:4, 640-646
     

278. 278

     Fu-Sheng Wang, Zheng Zhang. (2009) Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Review of Gastroenterology & Hepatology 3:5, 499-512
     

279. 279

     N. Coppola, A. Masiello, G. Tonziello, R. Pisapia, M. Pisaturo, C. Sagnelli, V. Messina, V. Iodice, E. Sagnelli. (2009) Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. Journal of Viral Hepatitis
     

280. 280

     Dongling Li, Linghua Zheng, Lei Jin, Yuesu Zhou, Haiying Li, Junliang Fu, Ming Shi, Peishuang Du, Lizhong Wang, Hao Wu, Guo-Yun Chen, Pan Zheng, Yang Liu, Fu-Sheng Wang, Shengdian Wang. (2009) CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology 50:3, 735-742
     

281. 281

     Yingjun Guo, Ding Ren, Xiaowen He, Fang Wang, Lei Jiang, Shuxia Song, Ying He, Shuhan Sun. (2009) A novel mouse model for immunogenic evaluation of human HBV vaccines. Vaccine 27:41, 5692-5699
     

282. 282

     Rui Xiang Lei, Hong Shi, Xiao Mou Peng, Yin Hong Zhu, Jie Cheng, Gui Hua Chen. (2009) Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology 50:3, 763-771
     

283. 283

     María E. Miquilena-Colina, Tamara Lozano-Rodríguez, Leonor García-Pozo, Alicia Sáez, Paola Rizza, Imerio Capone, Maria Rapicetta, Paola Chionne, Maria Capobianchi, Marina Selleri, Concetta Castilletti, Filippo Belardelli, Oreste Lo Iacono, Carmelo García-Monzón. (2009) Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine 27:41, 5654-5660
     

284. 284

     Wei-ying Zhang, Na Cai, Li-hong Ye, Xiao-dong Zhang. (2009) Transformation of human liver L-O2 cells mediated by stable HBx transfection. Acta Pharmacologica Sinica 30:8, 1153-1161
     

285. 285

     L. Bracciale, M. Fabbiani, A. Sansoni, L. Luzzi, L. Bernini, G. Zanelli. (2009) Impact of Hepatitis B Vaccination in Children Born to HBsAg-Positive Mothers: a 20-year Retrospective Study. Infection 37:4, 340-343
     

286. 286

     Bo Gao, Zhijian Duan, Wei Xu, Sidong Xiong. (2009) Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50:2, 424-433
     

287. 287

     Rami Moucari, Olivier Lada, Patrick Marcellin. (2009) Chronic hepatitis B: back to the future with HBsAg. Expert Review of Anti-infective Therapy 7:6, 633-636
     

288. 288

     Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Naruomi Komura, Kyoko Kobayashi, Kentaro Yoshioka. (2009) The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection. Journal of Gastroenterology 44:7, 751-756
     

289. 289

     Wei Jia, Yajing Liu, Wei Li, Yan Liu, Dajun Zhang, Peng Zhang, Ping Gong. (2009) Synthesis and in vitro anti-hepatitis B virus activity of 6H-[1]benzothiopyrano[4,3-b]quinolin-9-ols. Bioorganic & Medicinal Chemistry 17:13, 4569-4574
     

290. 290

     Hye Jin Kim, Hwa Seung Yoo, Jin Chul Kim, Chan Su Park, Mi Sun Choi, Mijee Kim, Hyangsoon Choi, Jung Sun Min, Yong Soo Kim, Seong Woo Yoon, Jeong Keun Ahn. (2009) Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. Journal of Ethnopharmacology 124:2, 189-196
     

291. 291

     David M Iser, Sharon R Lewin. (2009) Future directions in the treatment of HIV–HBV coinfection. HIV Therapy 3:4, 405-415
     

292. 292

     Jennifer Guy, Hal F. Yee. (2009) Health disparities in liver disease: Time to take notice and take action. Hepatology 50:1, 309-313
     

293. 293

     Sonia Roman, Arturo Panduro, Yadira Aguilar-Gutierrez, Montserrat Maldonado, Maclovia Vazquez-VanDyck, Erika Martinez-Lopez, Bertha Ruiz-Madrigal, Zamira Hernandez-Nazara. (2009) A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatology International 3:2, 343-355
     

294. 294

     Matthew F. Daley, Karen A. Hennessey, Cindy M. Weinbaum, Shannon Stokley, Laura P. Hurley, Lori A. Crane, Brenda L. Beaty, Jennifer C. Barrow, Christine I. Babbel, L. Miriam Dickinson, Allison Kempe. (2009) Physician Practices Regarding Adult Hepatitis B Vaccination. American Journal of Preventive Medicine 36:6, 491-496
     

295. 295

     Kazuhiko Hayashi, Yoshiaki Katano, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Hidemi Goto. (2009) Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy. Clinical Journal of Gastroenterology 2:3, 210-213
     

296. 296

     Elisabete Arrese, Miren Basaras, Sonia Blanco, Pablo Ruiz, Ramon Cisterna. (2009) Monitoring of therapy in patients with chronic hepatitis B virus. European Journal of Gastroenterology & Hepatology1
     

297. 297

     Chaiyaphruk Pilakasiri, Robert V. Gibbons, Richard G. Jarman, Somjai Supyapoung, Khin Saw Aye Myint. (2009) Hepatitis antibody profile of Royal Thai Army nursing students. Tropical Medicine & International Health 14:6, 609-611
     

298. 298

     Lise L. Gluud, Christian Gluud. (2009) Meta-analyses on Viral Hepatitis. Infectious Disease Clinics of North America 23:2, 315-330
     

299. 299

     Julie Bottero, Karine Lacombe, Jérôme Guéchot, Lawrence Serfaty, Patrick Miailhes, Philippe Bonnard, Dominique Wendum, Jean-Michel Molina, Caroline Lascoux-Combe, Pierre-Marie Girard. (2009) Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. Journal of Hepatology 50:6, 1074-1083
     

300. 300

     Saleem Kamili, Vitini Sozzi, Geoff Thompson, Katie Campbell, Christopher M. Walker, Stephen Locarnini, Krzysztof Krawczynski. (2009) Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 49:5, 1483-1491
     

301. 301

     Ming-Jen Sheu, Hsing-Tao Kuo, Ching-Yih Lin, Lok-Beng Koay, Chuan Lee, Jyh-Jou Chen, Ling-Yu Tang, Sun-Lung Tsai. (2009) Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited. European Journal of Gastroenterology & Hepatology 21:4, 447-451
     

302. 302

     Weiwei Chen, Ming Shi, Feng Shi, Yuanli Mao, Zirong Tang, Bin Zhang, Hui Zhang, Liangen Chen, Liming Chen, Shaojie Xin, Fu-sheng Wang. (2009) HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatology Research 39:4, 355-365
     

303. 303

     Hai Cheng, Haixia Su, Suping Wang, Zhongjun Shao, Ke Men, Mingzheng Li, Shuzhen Li, Jingxia Zhang, Jianqiu Xu, Huiqin Zhang, Yongping Yan, Dezhong Xu. (2009) Association between genomic heterogeneity of hepatitis B virus and intrauterine infection. Virology 387:1, 168-175
     

304. 304

     Tao Jiang, Zhen-Gang Wang, Jianzhong Wu. (2009) Electrostatic Regulation of Genome Packaging in Human Hepatitis B Virus. Biophysical Journal 96:8, 3065-3073
     

305. 305

     Teeraporn Chinchai, Chintana Chirathaworn, Kesmanee Praianantathavorn, Apiradee Theamboonlers, Yanee Hutagalung, Bock P. Hans L., Pattarawat Thantiworasit, Yong Poovorawan. (2009) Long-Term Humoral and Cellular Immune Response to Hepatitis B Vaccine in High-Risk Children 18–20 Years After Neonatal Immunization. Viral Immunology 22:2, 125-130
     

306. 306

     Yen-Cheng Lin, En-Chi Hsu, Ling-Pai Ting. (2009) Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB. Cellular Microbiology 11:4, 645-660
     

307. 307

     Bin Cheng, Xiaorong Guo, Yaochu Zheng, Ying Wang, Chunyan Liu, Peiyuan Li. (2009) The effects of HBx gene on the expression of DNA repair enzymes hOGG1 and hMYHα mRNA in HepG2 cells. Journal of Huazhong University of Science and Technology [Medical Sciences] 29:2, 187-192
     

308. 308

     Susanne Abbrederis, Wolfgang Vogel. (2009) Hepatitis B. Wiener klinische Wochenschrift Education 4:1, 43-55
     

309. 309

     Amir Shlomai, Yosef Shaul. (2009) The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. Biochemical and Biophysical Research Communications 381:4, 544-548
     

310. 310

     Toru Takahashi, Tadashi Koike, Shigeo Hashimoto, Tomofumi Miura, Junichiro Nakamura, Satoshi Yamada, Tsutomu Miura, Masahiko Yanagi, Kazuhide Yamazaki, Shogo Okoshi, Yutaka Aoyagi. (2009) A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma. Hepatology International 3:1, 316-322
     

311. 311

     Jianghua Wang, Dong Jiang, Henghui Zhang, Sa Lv, Huiying Rao, Ran Fei, Lai Wei. (2009) Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. PROTEOMICS 9:6, 1672-1682
     

312. 312

     L. Lu, H.-Y. Zhang, Y.-H. Yueng, K.-F. Cheung, J. M. Luk, F.-S. Wang, G. K. K. Lau. (2009) Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients. Journal of Viral Hepatitis 16:2, 104-112
     

313. 313

     Chun-Chi Chen, Cheng-Pu Sun, Hsin-I Ma, Cheng-Chieh Fang, Pin-Yi Wu, Xiao Xiao, Mi-Hua Tao. (2009) Comparative Study of Anti-hepatitis B Virus RNA Interference by Double-stranded Adeno-associated Virus Serotypes 7, 8, and 9. Molecular Therapy 17:2, 352-359
     

314. 314

     Emanuel K. Manesis. (2009) The natural history of chronic HBV infection. Current Hepatitis Reports 8:1, 10-17
     

315. 315

     (2009) EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology 50:2, 227-242
     

316. 316

     Chia-Sui Hung, Yu-Li Lin, Chun-I Wu, Chiu-Jung Huang, Ling-Pai Ting. (2009) Suppression of hepatitis B viral gene expression by phosphoinositide 5-phosphatase SKIP. Cellular Microbiology 11:1, 37-50
     

317. 317

     J. L. Starkey, E. F. Chiari, H. C. Isom. (2009) Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. Journal of General Virology 90:1, 115-126
     

318. 318

     Cheng Wu, Zhanfeng Wang, Lijie Liu, Peng Zhao, Wenjing Wang, Dingkang Yao, Bing Shi, Junhua Lu, Ping Liao, Yaning Yang, Liang Zhu. (2009) Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 24:1, 55-62
     

319. 319

     Ioannis S. Elefsiniotis, Christos Pavlidis, Elena Vezali, Theodoros Mariolis-Sapsakos, Sotirios Koutsounas, George Saroglou. (2009) Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients. Gastroenterology Research and Practice 2009, 1-5
     

320. 320

     Yun Gyu Park. (2009) Inhibition of hepatitis B virus replication by RNA interference. The Korean Journal of Hepatology 15:1, 1
     

321. 321

     Masahiko Koda, Takakazu Nagahara, Tomomitu Matono, Takaaki Sugihara, Mari Mandai, Masaru Ueki, Kenji Ohyama, Keiko Hosho, Junichi Okano, Yukihiro Kishimoto, Michimori Kono, Shigeo Maruyama, Yoshikazu Murawaki. (2009) Nucleotide Analogs for Patients with HBV-Related Hepatocellular Carcinoma Increase the Survival Rate through Improved Liver Function. Internal Medicine 48:1, 11-17
     

322. 322

     Patrick Leenheer. (2009) Within-Host Virus Models with Periodic Antiviral Therapy. Bulletin of Mathematical Biology 71:1, 189-210
     

323. 323

     Michael Nassal. (2009) New insights into HBV replication: new opportunities for improved therapies. Future Virology 4:1, 55-70
     

324. 324

     Sarene Koh, Antonio Bertoletti. (2009) Viral hepatitis and serotonin: altering cytotoxic T-lymphocyte function in the liver. Expert Review of Vaccines 8:1, 29-32
     

325. 325

     Sarah Katen, Adam Zlotnick. Chapter 14 The Thermodynamics of Virus Capsid Assembly. Elsevier, 2009:395-417.
     

326. 326

     D Martin, J S Gutkind. (2008) Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 27, S31-S42
     

327. 327

     Cihan Yurdaydin. (2008) Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 9:17, 3095-3109
     

328. 328

     Matthew B. Carroll, Michael I. Bond. (2008) Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B Infection. Seminars in Arthritis and Rheumatism 38:3, 208-217
     

329. 329

     Jia-Horng Kao, Ding-Shinn Chen. (2008) Universal Hepatitis B Vaccination: Killing 2 Birds with 1 Stone. The American Journal of Medicine 121:12, 1029-1031
     

330. 330

     Tarik Asselah, Olivier Lada, Rami Moucari, Patrick Marcellin. (2008) Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 17:12, 1963-1974
     

331. 331

     Andre Boonstra, Andrea M. Woltman, Harry L.A. Janssen. (2008) Immunology of hepatitis B and hepatitis C virus infections. Best Practice & Research Clinical Gastroenterology 22:6, 1049-1061
     

332. 332

     S. Domm, J. Cinatl, U. Mrowietz. (2008) The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. British Journal of Dermatology 159:6, 1217-1228
     

333. 333

     Karsten Wursthorn, Michael P. Manns, Heiner Wedemeyer. (2008) Natural history: The importance of viral load, liver damage and HCC. Best Practice & Research Clinical Gastroenterology 22:6, 1063-1079
     

334. 334

     Ioannis Goulis, George N Dalekos. (2008) Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Review of Anti-infective Therapy 6:6, 855-859
     

335. 335

     Jinfeng Liu, Yongqin Li, Tianyan Chen, Yuan Yang, Ke Wang, Yingli He, Qian Yang, Feng Ye, Yan Jin, Ting Qiu, Shumei Lin, Min Liu, Yingren Zhao. (2008) The distribution of HBV genotypes and clinical significance in familial clustering in an infected population with unfavorable prognosis. Archives of Virology 153:11, 2157-2161
     

336. 336

     T. Nagashima, S. Minota. (2008) Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 47:12, 1838-1840
     

337. 337

     Dienstag , Jules L. , . (2008) Hepatitis B Virus Infection. New England Journal of Medicine 359:14, 1486-1500
     Full Text

338. 338

     Eiji Tanaka, Takeji Umemura. (2008) History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clinical Journal of Gastroenterology 1:3, 83-86
     

339. 339

     Eui-Kyung Goh, Bong-Hyung Son, Soo-Keun Kong, Kyong-Myong Chon, Kyu-Sup Cho. (2008) Analysis of Hepatitis B Virus in the Cerumen and Otorrhea of Chronic HBV-Infected Patients. Otology & Neurotology 29:7, 929-932
     

340. 340

     Josef van Helden, Carl Cornely, Francesco Dati, H. Roma Levy, Tricia Bal, Mary Seeger, Theodore Wright, Lawrence Baker. (2008) Performance evaluation of the ADVIA Centaur® anti-HBe and HBeAg assays. Journal of Clinical Virology 43:2, 169-175
     

341. 341

     William Alazawi, Graham R Foster. (2008) Advances in the diagnosis and treatment of hepatitis B. Current Opinion in Infectious Diseases 21:5, 508-515
     

342. 342

     Jian-hua YIN. (2008) Role of HBV subgenotype C2,B2 in carcinogenesis,treatment and prognosis of hepatocellular carcinoma. Academic Journal of Second Military Medical University 28:2, 162-166
     

343. 343

     Masaru Enomoto, Akihiro Tamori, Madoka Toyama Kohmoto, Takehiro Hayashi, Hiroyasu Morikawa, Hisato Jomura, Hiroki Sakaguchi, Daiki Habu, Norifumi Kawada, Susumu Shiomi, Shuhei Nishiguchi. (2008) Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. Hepatology Research 38:9, 954-959
     

344. 344

     Zhiao Chen, Yuming Cheng, Yongfen Xu, Jing Liao, Xiaonan Zhang, Yunwen Hu, Qin Zhang, Jiefei Wang, Zhanqing Zhang, Fang Shen, Zhenghong Yuan. (2008) Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clinical Immunology 128:3, 400-408
     

345. 345

     Bo Kyung Kim, Seoung Ok Lim, Yun Gyu Park. (2008) Requirement of the cyclic adenosine monophosphate response element-binding protein for hepatitis B virus replication. Hepatology 48:2, 361-373
     

346. 346

     R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García. (2008) Tratamiento farmacológico de la hepatitis B. Farmacia Hospitalaria 32:4, 234-248
     

347. 347

     Jia-Horng Kao. (2008) Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Review of Gastroenterology & Hepatology 2:4, 553-562
     

348. 348

     W. S. AYOUB, E. B. KEEFFE. (2008) Review article: current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology & Therapeutics 28:2, 167-177
     

349. 349

     Xiao-Ye Wu, Jia-Jie Qian, Yi Lin, Ming-Hua Zheng. (2008) Hepatitis B virus X protein disrupts DNA interstrand crosslinking agent mitomycin C induced ATR dependent intra-S-phase checkpoint. European Journal of Cancer 44:11, 1596-1602
     

350. 350

     Kazuhiko Hayashi, Yoshiaki Katano, Yasushi Takeda, Takashi Honda, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto. (2008) Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. Journal of Gastroenterology 43:7, 558-564
     

351. 351

     Hye Jin Kim, Sang Yong Kim, Jinchul Kim, Heemin Lee, Misun Choi, Jeong Ki Kim, Jeong Keun Ahn. (2008) Hepatitis B virus X protein induces apoptosis by enhancing translocation of Bax to mitochondria. IUBMB Life 60:7, 473-480
     

352. 352

     L. Didierlaurent, L. Houzet, Z. Morichaud, J.-L. Darlix, M. Mougel. (2008) The conserved N-terminal basic residues and zinc-finger motifs of HIV-1 nucleocapsid restrict the viral cDNA synthesis during virus formation and maturation. Nucleic Acids Research 36:14, 4745-4753
     

353. 353

     Zheng Zhang, Ji–Yuan Zhang, E. John Wherry, Bo Jin, Bin Xu, Zheng–Sheng Zou, Shu–Ye Zhang, Bao–Sen Li, Hui–Feng Wang, Hao Wu, George K.K. Lau, Yang–Xin Fu, Fu–Sheng Wang. (2008) Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B. Gastroenterology 134:7, 1938-1949.e3
     

354. 354

     Michael Nassal. (2008) Hepatitis B viruses: Reverse transcription a different way. Virus Research 134:1-2, 235-249
     

355. 355

     D. L. VEENSTRA, D. E. SPACKMAN, A. BISCEGLIE, K. V. KOWDLEY, R. G. GISH. (2008) Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Alimentary Pharmacology & Therapeutics 27:12, 1240-1252
     

356. 356

     Marianne Bonvin, Jobst Greeve. (2008) Hepatitis B: modern concepts in pathogenesis ??? APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Current Opinion in Infectious Diseases 21:3, 298-303
     

357. 357

     Hiromi Yatsuji, Fumitaka Suzuki, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Sachiyo Watahiki, Satomi Iwasaki, Mariko Kobayashi, Hiromitsu Kumada. (2008) Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up. Journal of Hepatology 48:6, 923-931
     

358. 358

     Luisa García Buey, Fernando González Mateos, Ricardo Moreno Oteroa. (2008) Interferón en la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 26, 19-31
     

359. 359

     Adrian R. Levy, Kris V. Kowdley, Uchenna Iloeje, Eskinder Tafesse, Jayanti Mukherjee, Robert Gish, Natalie Bzowej, Andrew H. Briggs. (2008) The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value in Health 11:3, 527-538
     

360. 360

     Aiping Tong, Lihong Wu, Qingsong Lin, Quek Choon Lau, Xia Zhao, Jiong Li, Ping Chen, Lijuan Chen, Hong Tang, Canhua Huang, Yu-quan Wei. (2008) Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. PROTEOMICS 8:10, 2012-2023
     

361. 361

     Pilar Martinez Montiel, Jose Antonio Solis, Juan Antonio Chirinos, Begoń A Casis, Fernando Sánchez, Sarbelio Rodríguez. (2008) Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver International 28:5, 718-720
     

362. 362

     Willisa Liou, Yen-Jen Sung, Mi-Hwa Tao, Szecheng J. Lo. (2008) Morphogenesis of the hepatitis B virion and subviral particles in the liver of transgenic mice. Journal of Biomedical Science 15:3, 311-316
     

363. 363

     Dilip Ratnam, Kumar Visvanathan. (2008) New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatology International 2:S1, 12-18
     

364. 364

     Mei-Hwei Chang. (2008) Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatology International 2:S1, 28-36
     

365. 365

     J. Kock, H. E. Blum. (2008) Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. Journal of General Virology 89:5, 1184-1191
     

366. 366

     Chia-Chi Wang, Ching-Sheng Hsu, Chun-Jen Liu, Jia-Horng Kao, Ding-Shinn Chen. (2008) Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. Journal of Gastroenterology and Hepatology 23:5, 779-782
     

367. 367

     M.L. Galve Martn, E. Navarrete Garca, J. Iborra Herrera. (2008) Hepatitis por el virus C. Hepatitis por el virus B y otros virus hepatotropos. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 10:9, 548-554
     

368. 368

     J. Crespo, M. Lpez Lpez, M.T. Arias Loste. (2008) Hepatitis. Concepto. Clasificaci?n etiol?gica y patocr?nica. Mecanismos patog?nicos de da?o hep?tico. Historia natural. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 10:9, 541-547
     

369. 369

     Francesco Vitale, Fabio Tramuto, Ambrogio Orlando, Giovanni Vizzini, Valentina Meli, Giuseppe Cerame, Walter Mazzucco, Roberto Virdone, Ugo Palazzo, Maria Rosaria Villafrate, Alessandro Tagger, Nino Romano. (2008) Can the serological status of “anti-HBc alone” be considered a sentinel marker for detection of “occult” HBV infection?. Journal of Medical Virology 80:4, 577-582
     

370. 370

     Emilio Palumbo. (2008) New Drugs for Chronic Hepatitis B: A Review. American Journal of Therapeutics 15:2, 167-172
     

371. 371

     Kamol Suwannakarn, Pisit Tangkijvanich, Nutchanart Thawornsuk, Apiradee Theamboonlers, Piyanit Tharmaphornpilas, Pornsak Yoocharoen, Voranush Chongsrisawat, Yong Poovorawan. (2008) Molecular epidemiological study of hepatitis B virus in Thailand based on the analysis of pre-S and S genes. Hepatology Research 38:3, 244-251
     

372. 372

     Wei-zhe Deng, Qing-bo Lang, Chang-quan Ling. (2008) Relationship between abnormal characteristics of sublingual collateral and portal vein hemodynamic changes in patients with primary hepatic carcinoma. Chinese Journal of Integrative Medicine 14:1, 28-32
     

373. 373

     Teerha Piratvisuth, George Lau, You-Chen Chao, Rui Jin, Anuchit Chutaputti, Q.-B. Zhang, Tawesak Tanwandee, Peter Button, Matei Popescu. (2008) Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatology International 2:1, 102-110
     

374. 374

     José M. Sánchez-Tapias. (2008) Fármacos para el tratamiento de la hepatitis B crónica. Gastroenterología y Hepatología 31:3, 120-128
     

375. 375

     Ram Maya, M. Eric Gershwin, Yehuda Shoenfeld. (2008) Hepatitis B Virus (HBV) and Autoimmune Disease. Clinical Reviews in Allergy & Immunology 34:1, 85-102
     

376. 376

     Jean–Michel Pawlotsky, Geoffrey Dusheiko, Angelos Hatzakis, Daryl Lau, George Lau, T. Jake Liang, Stephen Locarnini, Paul Martin, Douglas D. Richman, Fabien Zoulim. (2008) Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach. Gastroenterology 134:2, 405-415
     

377. 377

     Patrick Marcellin, Françoise Pequignot, Elisabeth Delarocque-Astagneau, Jean-Pierre Zarski, Nathalie Ganne, Patrick Hillon, Denise Antona, Martine Bovet, Murielle Mechain, Tarik Asselah, Jean-Claude Desenclos, Eric Jougla. (2008) Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. Journal of Hepatology 48:2, 200-207
     

378. 378

     Emilio Palumbo. (2008) Entecavir For Chronic Hepatitis B: A Review. Therapeutic Drug Monitoring 30:1, 1-4
     

379. 379

     Guoping Peng, Shuping Li, Wei Wu, Xufei Tan, Yiqiong Chen, Zhi Chen. (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Molecular Immunology 45:4, 963-970
     

380. 380

     Robert M. Friedman. (2008) Clinical uses of interferons. British Journal of Clinical Pharmacology 65:2, 158-162
     

381. 381

     Xiao-Ben Pan, Lai Wei, Jin-Chao Han, Yan Gao. (2008) Cellular chromosome DNA interferes with fluorescence quantitative real-time PCR detection of HBV DNA in culture medium. Journal of Medical Virology 80:1, 47-52
     

382. 382

     Katherine E Marschall. Diseases of the Liver and Biliary Tract. In: Stoelting's Anesthesia and Co-Existing Disease. Elsevier, 2008:259-278.
     

383. 383

     Felix Bohne, Markus Chmielewski, Gregor Ebert, Katja Wiegmann, Timo Kürschner, Andreas Schulze, Stephan Urban, Martin Krönke, Hinrich Abken, Ulrike Protzer. (2008) T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes. Gastroenterology 134:1, 239-247
     

384. 384

     Geoffrey Férir, Suzanne Kaptein, Johan Neyts, Erik De Clercq. (2008) Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Reviews in Medical Virology 18:1, 19-34
     

385. 385

     Hsiu-Ting Tsai, Tzu-Hsin Tsai, Tsong-Ming Lu, Chi-Chiang Yang. (2008) Immunopathology of Hepatitis B Virus Infection. International Reviews of Immunology 27:6, 427-446
     

386. 386

     D Eldon Spackman, David L Veenstra. (2008) A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B. PharmacoEconomics 26:11, 937-949
     

387. 387

     Kyeh Dong Shi, Seong Gyu Hwang, Ju Hyun Choi, Il Joon Hwang, Jai Ho Yoon, Kwang Il Kim, Chang-Il Kwon, Sung Pyo Hong, Pil Won Park, Kyu Sung Rim. (2008) Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B. The Korean Journal of Hepatology 14:2, 197
     

388. 388

     R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García. (2008) Drugs Treatment of Hepatitis B. Farmacia Hospitalaria (English Edition) 32:4, 234-248
     

389. 389

     Peter N. Bennett, Morris J. Brown. Liver, biliary tract, pancreas. In: Clinical Pharmacology. Elsevier, 2008:582-590.
     

390. 390

     Hans-Jürgen Netter, Shau-Feng Chang, Michael Bruns. (2008) Host-range and pathogenicity of hepatitis B viruses. Future Virology 3:1, 83-94
     

391. 391

     ESKILD PETERSEN. (2007) Protozoan and helminth infections in pregnancy. Short-term and long-term implications of transmission of infection from mother to foetus. Parasitology 134:13,
     

392. 392

     Hiromi Yatsuji, Nobuhiko Hiraga, Nami Mori, Tsuyoshi Hatakeyama, Masataka Tsuge, Michio Imamura, Shoichi Takahashi, Yoshifumi Fujimoto, Hidenori Ochi, Hiromi Abe, Toshiro Maekawa, Fumitaka Suzuki, Hiromitsu Kumada, Kazuaki Chayama. (2007) Successful treatment of an entecavir-resistant hepatitis B virus variant. Journal of Medical Virology 79:12, 1811-1817
     

393. 393

     Masaru Enomoto, Akihiro Tamori, Madoka Toyama Kohmoto, Hiroyasu Morikawa, Daiki Habu, Hiroki Sakaguchi, Tadashi Takeda, Shuichi Seki, Norifumi Kawada, Susumu Shiomi, Shuhei Nishiguchi. (2007) Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: Analyses of the polymerase gene and full-length sequences. Journal of Medical Virology 79:11, 1664-1670
     

394. 394

     Timothy M. Block, Haitao Guo, Ju-Tao Guo. (2007) Molecular Virology of Hepatitis B Virus for Clinicians. Clinics in Liver Disease 11:4, 685-706
     

395. 395

     Robert G. Gish, Anna S. Lok, Ting–Tsung Chang, Robert A. de Man, Adrian Gadano, José Sollano, Kwang–Hyub Han, You–Chen Chao, Shou–Dong Lee, Melissa Harris, Joanna Yang, Richard Colonno, Helena Brett–Smith. (2007) Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. Gastroenterology 133:5, 1437-1444
     

396. 396

     F. Bohne, U. Protzer. (2007) Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B. Journal of Viral Hepatitis 14:s1, 45-50
     

397. 397

     Dan Rudin, Sooraj M. Shah, Alexander Kiss, Robert V. Wetz, Vincent M. Sottile. (2007) Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver International 27:9, 1185-1193
     

398. 398

     Emmet B. Keeffe. (2007) Hepatitis B: Explosion of New Knowledge. Gastroenterology 133:5, 1718-1721
     

399. 399

     Gloria D. Coronado, Victoria M. Taylor, Shin-Ping Tu, Yutaka Yasui, Elizabeth Acorda, Erica Woodall, Mei-Po Yip, Lin Li, T. Gregory Hislop. (2007) Correlates of Hepatitis B Testing Among Chinese Americans. Journal of Community Health 32:6, 379-390
     

400. 400

     En-Chi Hsu, Yen-Cheng Lin, Chia-Shia Hung, Chiu-Jung Huang, Mei-Yi Lee, Shun-Chun Yang, Ling-Pai Ting. (2007) Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3. Journal of Biomedical Science 14:6, 731-744
     

401. 401

     C. Liu, B. Cheng. (2007) Association of polymorphisms of human leucocyte antigen-DQA1 and DQB1 alleles with chronic hepatitis B virus infection, liver cirrhosis and hepatocellular carcinoma in Chinese. International Journal of Immunogenetics 34:5, 373-378
     

402. 402

     Giuseppina Raffa, Sergio Maimone, Antonietta Cargnel, Teresa Santantonio, Giorgio Antonucci, Marco Massari, Monica Schiavini, Gaia Caccamo, Teresa Pollicino, Giovanni Raimondo. (2007) Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21:16, 2171-2175
     

403. 403

     Isabel García Bermejo. (2007) Anomalías y patrones serológicos infrecuentes de los marcadores diagnósticos del virus de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 25, 21-28
     

404. 404

     Sammy Saab, Mamie H. Dong, Tom A. Joseph, Myron J. Tong. (2007) Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model. Hepatology 46:4, 1049-1056
     

405. 405

     X. M. Peng, R. X. Lei, L. Gu, H. H. Ma, Q. F. Xie, Z. L. Gao. (2007) Influences of MxA gene ?88 G/T and IFN-gamma +874 A/T on the natural history of hepatitis B virus infection in an endemic area. International Journal of Immunogenetics 34:5, 341-346
     

406. 406

     María Buti, Francisco Rodríguez Frías, José Luis Calleja, Rosendo Jardí, Fernando Pons, Javier Crespo, Teresa Casanovas, Jaime Enríquez, Fernando Carnicer, Manuel Romero, Manuel García Bengoechea, Martín Prieto, Javier García Samaniego, Manuel Miras, Francisco Pérez Roldán, Magdalena Rueda, Rafael Esteban. (2007) Programa de uso compasivo con adefovir dipivoxil en España: valoración de su eficacia y estudio de las resistencias. Medicina Clínica 129:15, 566-570
     

407. 407

     Fu-Sheng Wang. (2007) Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: Progress and challenges. Hepatology Research 37:s3, S339-S346
     

408. 408

     H.-W. Hann, S.-H. Han, T. M. Block, M. Harris, J.-F. Maa, R. T. Fisher, E. Atillasoy. (2007) Symptomatology and health attitudes of chronic hepatitis B patients in the USA. Journal of Viral Hepatitis 0:0, 070924202706005-???
     

409. 409

     M. Ulcickas Yood, C. P. Quesenberry, D. Guo, K. Wells, J. Shan, L. Sanders, M. L. Skovron, U. Iloeje, C. Caldwell, M. M. Manos. (2007) Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm. Journal of Viral Hepatitis 0:0, 070924202706001-???
     

410. 410

     Jiefeng Cui, Xiaonan Kang, Zhi Dai, Cheng Huang, Haijun Zhou, Kun Guo, Yan Li, Yu Zhang, Ruixia Sun, Jie Chen, Yang Li, Zhaoyou Tang, Toshimasa Uemura, Yinkun Liu. (2007) Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. Journal of Cancer Research and Clinical Oncology 133:11, 825-834
     

411. 411

     Thomas F. Baumert, Christine Rösler, Michael H. Malim, Fritz von Weizsäcker. (2007) Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 46:3, 682-689
     

412. 412

     P. Miailhes, M.-A. Trabaud, P. Pradat, B. Lebouche, M. l. Chevallier, P. Chevallier, F. Zoulim, C. Trepo. (2007) Impact of Highly Active Antiretroviral Therapy (HAART) on the Natural History of Hepatitis B Virus (HBV) and HIV Coinfection: Relationship between Prolonged Efficacy of HAART and HBV Surface and Early Antigen Seroconversion. Clinical Infectious Diseases 45:5, 624-632
     

413. 413

     S. Pungpapong, W. R. Kim, J. J. Poterucha. (2007) Natural History of Hepatitis B Virus Infection: An Update for Clinicians. Mayo Clinic Proceedings 82:8, 967-975
     

414. 414

     J.-F. CADRANEL, P. LAHMEK, X. CAUSSE, G. BELLAICHE, L. BETTAN, T. FONTANGES, A. MEDINI, J. HENRION, M. CHOUSTERMAN, B. CONDAT, P. HERVIO, P. PERIAC, C. EUGÈNE, H. MOINDROT, D. GRASSET, O. NOUEL, C. PILETTE, N. SZOSTAK-TALBODEC, J.-M. CAYLA, S. N. SI-AHMED, P. DUMOUCHEL, A. PARIENTE, B. LESGOURGUES, J. DENIS. (2007) Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis - results of a nationwide survey. Alimentary Pharmacology & Therapeutics 26:4, 565-576
     

415. 415

     Wei Zhang, Xuzhao Zhang, C. Tian, Tao Wang, Phuong Thi Nguyen Sarkis, Yongmin Fang, Shu Zheng, Xiao-Fang Yu, Rongzhen Xu. (2007) Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cellular Microbiology 0:0, 070801234236001-???
     

416. 416

     Uchenna H. Iloeje, Hwai–I. Yang, Chin–Lan Jen, Jun Su, Li–Yu Wang, San–Lin You, Chien–Jen Chen. (2007) Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology 5:8, 921-931
     

417. 417

     Y. L. He, Y. R. Zhao, S. L. Zhang, S. M. Lin, W. Chen, J. F. Liu, Y. Yang, M. Liu, Y. R. Chen. (2007) Defects in the apoptotic machinery are associated with hepatic damage. Journal of Viral Hepatitis 14:7, 520-522
     

418. 418

     R. Bridget Ferns, Nikolai V. Naoumov, Richard J. Gilson, Richard S. Tedder. (2007) Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. Journal of Clinical Virology 39:3, 199-204
     

419. 419

     Mouna Mhamdi, Anneke Funk, Heinz Hohenberg, Hans Will, Hüseyin Sirma. (2007) Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles. Hepatology 46:1, 95-106
     

420. 420

     Ivana Carey, Diego Vergani. (2007) The Role of Viral-specific Immune Responses on the Outcome of Chronic Hepatitis B (HBV) Infection in Children: New Insights Into Immunopathology. Journal of Pediatric Gastroenterology and Nutrition 45:1, 15-18
     

421. 421

     Dan Rudin. (2007) Lamivudine and interferon versus lamivudine monotherapy for HBeAg-Positive hepatitis B treatment: A meta-analysis of randomized, controlled trials. Advances in Therapy 24:4, 784-795
     

422. 422

     Marianne Ulcickas Yood, Charles P. Quesenberry, Dianlin Guo, Cary Caldwell, Karen Wells, Jun Shan, Lynn Sanders, Mary Lou Skovron, Uchenna Iloeje, M. Michele Manos. (2007) Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 46:1, 107-112
     

423. 423

     S. Wendel. (2007) Rational testing for transmissible diseases. ISBT Science Series 2:1, 19-24
     

424. 424

     I-Chin Wu, Nan-Haw Chow, Pin-Nan Cheng, Wen-Chun Liu, Kung-Chia Young, Wei-Lun Chang, Chi-Yi Chen, Kuo-Chih Tseng, Ting-Tsung Chang. (2007) Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B. Journal of Medical Virology 79:6, 663-669
     

425. 425

     Mei-Hwei Chang. (2007) Hepatitis B virus infection. Seminars in Fetal and Neonatal Medicine 12:3, 160-167
     

426. 426

     Howard L. Lipton, Zhiguo Liang, Shannon Hertzler, Kyung-No Son. (2007) A specific viral cause of multiple sclerosis: One virus, one disease. Annals of Neurology 61:6, 514-523
     

427. 427

     Silvia Bondini, Jillian Kallman, Angela Wheeler, Shivaani Prakash, Terry Gramlich, Daniel M. Jondle, Zobair M. Younossi. (2007) Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver International 27:5, 607-611
     

428. 428

     Benyan Luo, Yanwen Wang, Kang Wang. (2007) Association of metabolic syndrome and hepatitis B infection in a Chinese population. Clinica Chimica Acta 380:1-2, 238-240
     

429. 429

     Tony Andreani, Lawrence Serfaty, Djamila Mohand, Salem Dernaika, Dominique Wendum, Olivier Chazouillères, Raoul Poupon. (2007) Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. Clinical Gastroenterology and Hepatology 5:5, 636-641
     

430. 430

     Andrés Ruiz-Sancho, Julie Sheldon, Vincent Soriano. (2007) Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy 7:5, 751-761
     

431. 431

     Fabien Zoulim. (2007) Emerging drugs for hepatitis B. Expert Opinion on Emerging Drugs 12:2, 199-217
     

432. 432

     Silvina Laura Malmassari, Qiang Deng, Hélène Fontaine, Dianne Houitte, François Rimlinger, Valérie Thiers, Bernard Maillere, Stanislas Pol, Marie-Louise Michel. (2007) Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology 45:5, 1199-1209
     

433. 433

     Simone M. Plas, Bettina E. Hansen, Josien B. Boer, Theo Stijnen, Jan Passchier, Rob A. Man, Solko W. Schalm. (2007) Generic and disease-specific health related quality of life of liver patients with various aetiologies: A survey. Quality of Life Research 16:3, 375-388
     

434. 434

     Songcheng YING, Xuzhao ZHANG, Phuong Thi Nguyen SARKIS, Rongzhen XU, Xiaofang YU. (2007) Cell-specific Regulation of APOBEC3F by Interferons. Acta Biochimica et Biophysica Sinica 39:4, 297-304
     

435. 435

     Matteo Iannacone, Giovanni Sitia, Zaverio M. Ruggeri, Luca G. Guidotti. (2007) HBV pathogenesis in animal models: Recent advances on the role of platelets. Journal of Hepatology 46:4, 719-726
     

436. 436

     Erika Santos Corraliza, Aurelio Fuertes Martín. (2007) Aspectos actuales de la patogenia, diagnóstico y tratamiento de la hepatitis B. Medicina Clínica 128:15, 579-583
     

437. 437

     Kazuhiko Hayashi, Yoshiaki Katano, Yasushi Takeda, Takashi Honda, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Motoyoshi Yano, Hidemi Goto, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada. (2007) Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. Journal of Medical Virology 79:4, 366-373
     

438. 438

     David L. Lewis, Jon A. Wolff. (2007) Systemic siRNA delivery via hydrodynamic intravascular injection. Advanced Drug Delivery Reviews 59:2-3, 115-123
     

439. 439

     Masaru Enomoto, Akihiro Tamori, Madoka Toyama Kohmoto, Takehiro Hayashi, Hisato Jomura, Daiki Habu, Hiroki Sakaguchi, Tadashi Takeda, Norifumi Kawada, Shuichi Seki, Susumu Shiomi, Noritoshi Koh, Shuhei Nishiguchi. (2007) Lamivudine and IFN- β Sequential Therapy in HBe Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. Journal of Interferon & Cytokine Research 27:3, 201-208
     

440. 440

     Emmet B. Keeffe, Patrick Marcellin. (2007) New and Emerging Treatment of Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 5:3, 285-294
     

441. 441

     Robert G. Gish. (2007) Improving outcomes for patients with chronic hepatitis B. Current Gastroenterology Reports 9:1, 14-22
     

442. 442

     I-Che Feng, Lok-Beng Koay, Ming-Jen Sheu, Hsing-Tao Kuo, Chi-Shu Sun, Chuan Lee, Wong-Lung Chuang, Shuen-Kuei Liao, Shih-Ling Wang, Ling-Yu Tang, Chia-Ju Cheng, Sun-Lung Tsai. (2007) HBcAg-specific CD4+CD25+regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. Journal of Biomedical Science 14:1, 43-57
     

443. 443

     M. Shi, S. Qian, W.-W. Chen, H. Zhang, B. Zhang, Z.-R. Tang, Z. Zhang, F.-S. Wang. (2007) Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clinical & Experimental Immunology 147:2, 277-286
     

444. 444

     Yong-Xiang Wang, Xiang Xu, Cheng Luo, Zhang-Mei Ma, Hua-Liang Jiang, Jian-Ping Ding, Yu-Mei Wen. (2007) Mutational analysis revealed that conservation of hepatitis B virus reverse transcriptase residue 306 (rtP306) is crucial for encapsidation of pregenomic RNA. FEBS Letters 581:3, 558-564
     

445. 445

     Zheng Zhang, Dawei Chen, Jinxia Yao, Hui Zhang, Lei Jin, Ming Shi, Hongfei Zhang, Fu-Sheng Wang. (2007) Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clinical Immunology 122:2, 173-180
     

446. 446

     Juarez A.S. Quaresma, Vera L.R.S. Barros, Carla Pagliari, Elaine R. Fernandes, Heitor F. Andrade, Pedro F.C. Vasconcelos, Maria I.S. Duarte. (2007) Hepatocyte lesions and cellular immune response in yellow fever infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 101:2, 161-168
     

447. 447

     Nermin N. Salkic, Muharem Zildzic, Kasim Muminhodzic, Nada Pavlovic-Calic, Enver Zerem, Sead Ahmetagic, Slavica Mott-Divkovic, Ervin Alibegovic. (2007) Intrafamilial transmission of hepatitis B in Tuzla region of Bosnia and Herzegovina. European Journal of Gastroenterology & Hepatology 19:2, 113-118
     

448. 448

     J Judy Chang, Sharon R Lewin. (2007) Immunopathogenesis of hepatitis B virus infection. Immunology and Cell Biology 85:1, 16-23
     

449. 449

     Giovanni Raimondo, Teresa Pollicino, Irene Cacciola, Giovanni Squadrito. (2007) Occult hepatitis B virus infection. Journal of Hepatology 46:1, 160-170
     

450. 450

     Neung Hwa Park, Young-Hwa Chung. (2007) Molecular Mechanisms of Hepatitis B Virus-associated Hepatocellular Carcinoma. The Korean Journal of Hepatology 13:3, 320
     

451. 451

     Danbi Lee, Young-Hwa Chung, Sae Hwan Lee, Yoon-Seon Lee, Don Lee, Jeong Eun Hwang, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Eunsil Yu, Young Sang Lee, Dong Jin Suh. (2007) Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B. Gut and Liver 1:1, 49
     

452. 452

     Susan J Keam. (2007) Telbivudine. Drugs 67:13, 1917-1929
     

453. 453

     C-C Chen, T-M Ko, H-I Ma, H-L Wu, X Xiao, J Li, C-M Chang, P-Y Wu, C-H Chen, J-M Han, C-P Yu, K-S Jeng, C-P Hu, M-H Tao. (2007) Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Therapy 14:1, 11-19
     

454. 454

     Neung Hwa Park, Il Han Song, Young-Hwa Chung. (2007) Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma. Gut and Liver 1:2, 101
     

455. 455

     David L Veenstra, Sean D Sullivan, Lauren Clarke, Uche H Iloeje, Eskinder Tafesse, Adrian Di Bisceglie, Kris V Kowdley, Robert G Gish. (2007) Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. PharmacoEconomics 25:11, 963-977
     

456. 456

     H.L. WANG, E.M. BRUNT. Cirrhosis and Portal Hypertension: Pathologic Aspects. In: Surgery of the Liver, Biliary Tract and Pancreas. Elsevier, 2007:1527-1540.
     

457. 457

     Shi-Jun Zhang, Ze-Xiong Chen, Kai-Ping Jiang, Wei-Kang Wu, Cui-Yi Zhang, Yan-Li Gu. (2006) Effect of seasonal variation on the clinical course of chronic hepatitis B. Journal of Gastroenterology 41:11, 1107-1115
     

458. 458

     Daniel Yerly, Loriana Di Giammarino, Florian Bihl, Andreas Cerny. (2006) Targets of emerging therapies for viral hepatitis B and C. Expert Opinion on Therapeutic Targets 10:6, 833-850
     

459. 459

     Wei Hou, Qin Ni, Jianer Wo, Minwei Li, Kezhou Liu, Liwei Chen, Zhongrong Hu, Ronghua Liu, Minjun Hu. (2006) Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes. Antiviral Research 72:3, 190-196
     

460. 460

     S.E. Moses, Z.Y. Lim, M. Sudhanva, S. Devereux, A.Y.L. Ho, A. Pagliuca, M. Zuckerman, G.J. Mufti. (2006) Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. Journal of Medical Virology 78:12, 1560-1563
     

461. 461

     Françoise Bouchardeau, Annie Girault, Annie Razer, Annabelle Servant-Delmas, Mélanie Mercier, Syria Laperche. (2006) Sensitivity of hepatitis B virus DNA transcription-mediated amplification testing in hepatitis B surface antigen?positive blood donations. Transfusion 46:12, 2047-2052
     

462. 462

     George Kinghorn. Viral Sexually Transmitted Infections. In: Gynecological Drug Therapy. CRC Press, 2006:269-286.
     

463. 463

     Dianxing Sun, Michael Nassal. (2006) Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. Journal of Hepatology 45:5, 636-645
     

464. 464

     S K Olsen, R S Brown. (2006) Hepatitis B treatment: Lessons for the nephrologist. Kidney International
     

465. 465

     E. Fraga Rivas, P. Barrera Baena, M. de la Mata García. (2006) Tratamiento de la resistencia al VHB. Gastroenterología y Hepatología 29, 59-64
     

466. 466

     Anthony Pajot, Marie-Louise Michel, Maryline Mancini-Bourgine, Marie-Noelle Ungeheuer, David M. Ojcius, Qiang Deng, François A. Lemonnier, Yu-Chun Lone. (2006) Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes and Infection 8:12-13, 2783-2790
     

467. 467

     Jon W. Gregersen, Kamil R. Kranc, Xiayi Ke, Pia Svendsen, Lars S. Madsen, Allan Randrup Thomsen, Lon R. Cardon, John I. Bell, Lars Fugger. (2006) Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature
     

468. 468

     Lu Tian, Stephen Lagakos. (2006) Analysis of a Partially Observed Binary Covariate Process and a Censored Failure Time in the Presence of Truncation and Competing Risks. Biometrics 62:3, 821-828
     

469. 469

     Armando Sánchez-Quijano, Eduardo Lissen. (2006) Tratamiento de las hepatitis víricas (I). Tratamiento de la hepatitis crónica B. Enfermedades Infecciosas y Microbiología Clínica 24:7, 453-462
     

470. 470

     Marina Núñez, Belén Ramos, Beatriz Díaz-Pollán, Nuria Camino, Luz Martín-Carbonero, Pablo Barreiro, Juan González-Lahoz, Vincent Soriano. (2006) Virological Outcome of Chronic Hepatitis B Virus Infection in HIV-Coinfected Patients Receiving Anti-HBV Active Antiretroviral Therapy. AIDS Research and Human Retroviruses 22:9, 842-848
     

471. 471

     Leonard A. Valentino, Veeral M. Oza. (2006) Blood safety and the choice of anti-hemophilic factor concentrate. Pediatric Blood & Cancer 47:3, 245-254
     

472. 472

     Jean-Pierre Zarski, Patrick Marcellin, Vincent Leroy, Christian Trepo, Didier Samuel, Nathalie Ganne-Carrie, Karl Barange, Valérie Canva, Michel Doffoel, Paul Cales. (2006) Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. Journal of Hepatology 45:3, 355-360
     

473. 473

     Xiaodong Zhang, Weiying Zhang, Lihong Ye. (2006) Pathogenesis of hepatitis B virus infection. Future Virology 1:5, 637-647
     

474. 474

     Cheng Ji, Neil Kaplowitz. (2006) ER stress: Can the liver cope?. Journal of Hepatology 45:2, 321-333
     

475. 475

     Emmet B. Keeffe. (2006) TREATMENT OF CHRONIC HEPATITIS B WITH ENTECAVIR: HIGH POTENCY AND ABSENT VIRAL RESISTANCE WITH 1 YEAR OF THERAPY. Evidence-Based Gastroenterology 7:3, 79-80
     

476. 476

     Shih-Hung Tsai, Hao-Ming Chang, Chung-Bao Hsieh, You-Chen Chao, Tsai-Yuan Hsieh. (2006) Acute fulminant hepatitis B in a patient with diabetic nephropathy treated successfully with concomitant lamivudine and molecular adsorbents recirculating system. Journal of Infection 53:1, e19-e23
     

477. 477

     Siobhán M. O'Connor, Christopher E. Taylor, James M. Hughes. (2006) Emerging Infectious Determinants of Chronic Diseases. Emerging Infectious Diseases 12:7, 1051-1057
     

478. 478

     Michael Chudy, Michael Schmidt, Volker Czudai, Heinrich Scheiblauer, Sigrid Nick, Mira Mosebach, Michael Kai Hourfar, Erhard Seifried, W. Kurt Roth, Elke Grünelt, C. Micha Nübling. (2006) Hepatitis B virus genotype G monoinfection and its transmission by blood components. Hepatology 44:1, 99-107
     

479. 479

     Feng Cao, John E. Tavis. (2006) Suppression of mRNA accumulation by the duck hepatitis B virus reverse transcriptase. Virology 350:2, 475-483
     

480. 480

     Marianne Bonvin, François Achermann, Isabell Greeve, Deborah Stroka, Adrian Keogh, Daniel Inderbitzin, Daniel Candinas, Peter Sommer, Simon Wain-Hobson, Jean-Pierre Vartanian, Jobst Greeve. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:6, 1364-1374
     

481. 481

     James Fung, Ching-Lung Lai, Man-Fung Yuen. (2006) Overcoming the problem of chronic hepatitis B. Drug Discovery Today: Therapeutic Strategies 3:2, 197-202
     

482. 482

     Morris Sherman, Cihan Yurdaydin, Jose Sollano, Marcelo Silva, Yun–Fan Liaw, Janusz Cianciara, Anna Boron–Kaczmarska, Paul Martin, Zachary Goodman, Richard Colonno, Anne Cross, Gail Denisky, Bruce Kreter, Robert Hindes. (2006) Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. Gastroenterology 130:7, 2039-2049
     

483. 483

     Fabien Zoulim, Julie Lucifora. (2006) Hepatitis B virus drug resistance: mechanism and clinical implications for the prevention of treatment failure. Future Virology 1:3, 361-376
     

484. 484

     Schildgen , Oliver , Sirma , Hueseyin , Funk , Anneke , Olotu , Cynthia , Wend , Ulrike C. Hartmann , Heinz , Helm , Martin Rockstroh , Jürgen K. , Willems , Wulf R. , Will , Hans , Gerlich , Wolfram H. , . (2006) Variant of Hepatitis B Virus with Primary Resistance to Adefovir. New England Journal of Medicine 354:17, 1807-1812
     Free Full Text

485. 485

     Chunshen Zhao, Yanfang Zhao, Huifang Chai, Ping Gong. (2006) Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates. Bioorganic & Medicinal Chemistry 14:8, 2552-2558
     

486. 486

     Xiao-Yuan Zi, Yu-Cheng Yao, Hai-Ying Zhu, Jun Xiong, Xiu-Ju Wu, Nan Zhang, Yue Ba, Wen-Lin Li, Xin-Ming Wang, Jian-Xiu Li, Hong-Yu Yu, Xu-Ting Ye, Joseph T. Y. Lau, Yi-Ping Hu. (2006) Long-term persistence of hepatitis B surface antigenand antibody induced by DNA-mediated immunization results in liver and kidney lesions in mice. European Journal of Immunology 36:4, 875-886
     

487. 487

     F. Zoulim, T. Poynard, F. Degos, A. Slama, A. El Hasnaoui, P. Blin, F. Mercier, P. Deny, P. Landais, P. Parvaz, C. Trepo, . (2006) A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. Journal of Viral Hepatitis 13:4, 278-288
     

488. 488

     Xiao Mou Peng, Yang Su Huang, Hui Hui Ma, Lin Gu, Qi Feng Xie, Zhi Liang Gao. (2006) Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver International 26:3, 326-333
     

489. 489

     K. Rösler, H. C. Spangenberg, H. E. Blum. (2006) Virushepatitis A–E. Der Gastroenterologe 1:2, 94-100
     

490. 490

     Timothy M. Block, Anand S. Mehta, Baruch S. Blumberg, Raymond A. Dwek. (2006) Does Rapid Oligomerization of Hepatitis B Envelope Proteins Play a Role in Resistance to Proteasome Degradation and Enhance Chronicity?. DNA and Cell Biology 25:3, 165-170
     

491. 491

     Flavia Bortolotti, Maria Guido, Samuela Bartolacci, Paolo Cadrobbi, Carlo Crivellaro, Franco Noventa, Giulia Morsica, Maria Moriondo, Angelo Gatta. (2006) Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology 43:3, 556-562
     

492. 492

     Andreas Untergasser, Uta Zedler, Anja Langenkamp, Marianna Hösel, Maria Quasdorff, Knud Esser, Hans-Peter Dienes, Barbara Tappertzhofen, Waldemar Kolanus, Ulrike Protzer. (2006) Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43:3, 539-547
     

493. 493

     Juarez Antonio Simões Quaresma, Vera Lucia Reis Souza Barros, Elaine Raniero Fernandes, Carla Pagliari, Fernanda Guedes, Pedro Fernando da Costa Vasconcelos, Heitor Franco de Andrade Junior, Maria Irma Seixas Duarte. (2006) Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Research 116:1-2, 91-97
     

494. 494

     Matteo Iannacone, Giovanni Sitia, Luca G Guidotti. (2006) Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology 1:2, 189-196
     

495. 495

     Hajo J. Flink, Monika van Zonneveld, Bettina E. Hansen, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, . (2006) Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype. The American Journal of Gastroenterology 101:2, 297-303
     

496. 496

     Marc G. Ghany, T. Jake Liang. (2006) Natural history of hbeag-negative chronic Hepatitis b. Current Hepatitis Reports 5:1, 27-32
     

497. 497

     Luca G. Guidotti, Francis V. Chisari. (2006) IMMUNOBIOLOGY AND PATHOGENESIS OF VIRAL HEPATITIS. Annual Review of Pathology: Mechanisms of Disease 1:1, 23-61
     

498. 498

     Winnie Yeo, Philip J. Johnson. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:2, 209-220
     

499. 499

     G. C. Farrell, N. C. Teoh. (2006) Management of chronic hepatitis B virus infection: a new era of disease control. Internal Medicine Journal 36:2, 100-113
     

500. 500

     Huifang Chai, Yanfang Zhao, Chunshen Zhao, Ping Gong. (2006) Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates. Bioorganic & Medicinal Chemistry 14:4, 911-917
     

501. 501

     Jia-Horng Kao, Ding-Shinn Chen. (2006) HBV genotypes: Epidemiology and implications regarding natural history. Current Hepatitis Reports 5:1, 5-13
     

502. 502

     Tetsuo Takehara, Takahiro Suzuki, Kazuyoshi Ohkawa, Atsushi Hosui, Masahisa Jinushi, Takuya Miyagi, Tomohide Tatsumi, Yoshiyuki Kanazawa, Norio Hayashi. (2006) Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. Journal of Hepatology 44:2, 267-274
     

503. 503

     M.H. van Roosmalen, J.J. de Jong, W. Haenen, T. Jacobs, F. Couwenberg, G.J.C.M. Ahlers-de Boer, J.A. Hellings. (2006) A New HBsAg Screening Assay Designed for Sensitive Detection of HBsAg Subtypes and Variants. Intervirology 49:3, 127-132
     

504. 504

     E. K. MANESIS, G. V. PAPATHEODORIDIS, S. J. HADZIYANNIS. (2006) A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Alimentary Pharmacology and Therapeutics 23:1, 99-106
     

505. 505

     John S. Bradley. Hepatitis. In: Infectious Diseases of the Fetus and Newborn Infant. Elsevier, 2006:823-843.
     

506. 506

     Tullia M. De Feo, Paolo Grossi, Francesca Poli, Fulvio Mozzi, Piergiorgio Messa, Enrico Minetti, Silvio Sandrini, Luigi Boschiero, Paolo Rigotti, Cristina Maresca, Davide Rolla, Stefano Chiaramonte, Eliana Gotti, Rossana Caldara, Giulio Briano, Mario Scalamogna. (2006) Kidney Transplantation from Anti-HBc+ Donors: Results from a Retrospective Italian Study. Transplantation 81:1, 76-80
     

507. 507

     Dean M Robinson, Lesley J Scott, Greg L Plosker. (2006) Entecavir. Drugs 66:12, 1605-1622
     

508. 508

     Xiaojuan Li, Ersheng Kuang, Wei Dai, Boping Zhou, Fuhua Yang. (2005) Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus. Virus Research 114:1-2, 126-132
     

509. 509

     Ke-zhou Liu, Wei Hou, Edward Zumbika, Qin Ni. (2005) Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. Journal of Zhejiang University SCIENCE B 6:12, 1182-1187
     

510. 510

     Jean-Michel Pawlotsky. (2005) The concept of hepatitis B virus mutant escape. Journal of Clinical Virology 34, S125-S129
     

511. 511

     Masataka Tsuge, Nobuhiko Hiraga, Hideki Takaishi, Chiemi Noguchi, Hiromi Oga, Michio Imamura, Shoichi Takahashi, Eiji Iwao, Yoshifumi Fujimoto, Hidenori Ochi, Kazuaki Chayama, Chise Tateno, Katsutoshi Yoshizato. (2005) Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42:5, 1046-1054
     

512. 512

     Eirini I. Rigopoulou, Deepak Suri, Shilpa Chokshi, Ivana Mullerova, Steven Rice, Richard S. Tedder, Roger Williams, Nikolai V. Naoumov. (2005) Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. Hepatology 42:5, 1028-1036
     

513. 513

     G. Zeng, Z. Wang, S. Wen, J. Jiang, L. Wang, J. Cheng, D. Tan, F. Xiao, S. Ma, W. Li, K. Luo, N. V. Naoumov, J. Hou. (2005) Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. Journal of Viral Hepatitis 12:6, 609-617
     

514. 514

     Myoung Kuk Jang, Dae Ro Choi, Ja Young Lee, Han Kook Moon, Jun Ho Lee, Seong Man Kim, Kyung Ho Kim, Joon Yong Park, Jin Heon Lee, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park, Jae Young Yoo. (2005) Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission. Journal of Infection 51:4, 314-317
     

515. 515

     Robert G. Gish. (2005) Current Treatment and Future Directions in the Management of Chronic Hepatitis B Viral Infection. Clinics in Liver Disease 9:4, 541-565
     

516. 516

     Alexis A. Gintowt, Jeffrey J. Germer, P. Shawn Mitchell, Joseph D.C. Yao. (2005) Evaluation of the MagNA Pure LC used with the TRUGENE™ HBV Genotyping Kit. Journal of Clinical Virology 34:2, 155-157
     

517. 517

     Jia-Horng Kao, Ding-Shinn Chen. (2005) Hepatitis B vaccination: to boost or not to boost?. The Lancet 366:9494, 1337-1338
     

518. 518

     Eleftheria K. Zervou, Nikolaos K. Gatselis, Epthemia Xanthi, Kostas Ziciadis, Sarah P. Georgiadou, Georgios N. Dalekos. (2005) Intrafamilial spread of hepatitis B virus infection in Greece. European Journal of Gastroenterology & Hepatology 17:9, 911-915
     

519. 519

     Patricia Santiago-Munoz, Scott Roberts, Jeanne Sheffield, Barbara McElwee, George D. Wendel. (2005) Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. American Journal of Obstetrics and Gynecology 193:3, 1270-1273
     

520. 520

     Xiao Mou Peng, Lin Gu, Yang Su Huang, Hui Hui Ma, Qi Feng Xie, Gang Li, Zhi Liang Gao. (2005) Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR. Journal of Virological Methods 128:1-2, 168-175
     

521. 521

     Christine Rösler, Josef Köck, Michael Kann, Michael H. Malim, Hubert E. Blum, Thomas F. Baumert, Fritz von Weizsäcker. (2005) APOBEC-mediated interference with hepadnavirus production. Hepatology 42:2, 301-309
     

522. 522

     REKHA PAL, RAKESH AGGARWAL, SUBHASH R NAIK, VINEETA DAS, SIDDHARTH DAS, SITA NAIK. (2005) Immunological alterations in pregnant women with acute hepatitis E. Journal of Gastroenterology and Hepatology 20:7, 1094-1101
     

523. 523

     C.M.D. Silva, C. Costi, C. Costa, C. Michelon, R. Oravec, A.B. Ramos, C. Niel, M.L. Rossetti. (2005) Low rate of occult hepatitis B virus infection among anti-HBc positive blood donors living in a low prevalence region in Brazil. Journal of Infection 51:1, 24-29
     

524. 524

     Irene Cacciola, Giovanna Spatari, Teresa Pollicino, Lucy Costantino, Giovanni Zimbaro, Santa Brancatelli, Concettina Fenga, Gaia Caccamo, Giovanni Squadrito, Giovanni Raimondo. (2005) Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study.. Liver International 25:3, 555-563
     

525. 525

     Karine Lacombe, Joël Gozlan, Pierre-Yves Boelle, Lawrence Serfaty, Fabien Zoulim, Alain-Jacques Valleron, Pierre-Marie Girard. (2005) Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19:9, 907-915
     

526. 526

     A.A. Peres, E.A. Dias, M. Chesky, M.R. Alvares-da-Silva, L.F. Jobim, L.F. Goncalves, R.C. Manfro. (2005) Occult hepatitis B in renal transplant patients. Transplant Infectious Disease 7:2, 51-56
     

527. 527

     Richard H Moseley. (2005) Liver and biliary tract disorders. Current Opinion in Gastroenterology 21:3, 257-259
     

528. 528

     Kiyoshi Migita, Seiji Miyazoe, Yumi Maeda, Manabu Daikoku, Seigo Abiru, Tshihito Ueki, Koji Yano, Shinya Nagaoka, Takehiro Matsumoto, Kazuhiko Nakao, Keisuke Hamasaki, Hiroshi Yatsuhashi, Hiromi Ishibashi, Katsumi Eguchi. (2005) Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—association between TGF-β1 polymorphisms and hepatocellular carcinoma. Journal of Hepatology 42:4, 505-510
     

529. 529

     Robert Thimme, Hans Christian Spangenberg, Hubert E. Blum. (2005) Hepatitis B or hepatitis C and human immunodeficiency virus infection. Journal of Hepatology 42:1, S37-S44
     

530. 530

     Chiemi Noguchi, Hiromi Ishino, Masataka Tsuge, Yoshifumi Fujimoto, Michio Imamura, Shoichi Takahashi, Kazuaki Chayama. (2005) G to A hypermutation of hepatitis B virus. Hepatology 41:3, 626-633
     

531. 531

     Jaisri R. Lingappa, Michael A. Newman, Kevin C. Klein, Julia E. Dooher. (2005) Comparing capsid assembly of primate lentiviruses and hepatitis B virus using cell-free systems. Virology 333:1, 114-123
     

532. 532

     Fabien Zoulim. (2005) New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. Journal of Hepatology 42:3, 302-308
     

533. 533

     Yongwook Choi, Sung Gyoo Park, Jun-hi Yoo, Guhung Jung. (2005) Calcium ions affect the hepatitis B virus core assembly. Virology 332:1, 454-463
     

534. 534

     Magdalena Robaczewska, Ramamurthy Narayan, Beatrice Seigneres, Olivier Schorr, Alexandre Thermet, Anna J. Podhajska, Christian Trepo, Fabien Zoulim, Peter E. Nielsen, Lucyna Cova. (2005) Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA). Journal of Hepatology 42:2, 180-187
     

535. 535

     Charles Cha, Ronald P. DeMatteo. (2005) Molecular mechanisms in hepatocellular carcinoma development. Best Practice & Research Clinical Gastroenterology 19:1, 25-37
     

536. 536

     Kang Mo Kim, Won-Beom Choi, Young-Suk Lim, Han-Chu Lee, Young-Hwa Chung, Young-Sang Lee, Dong-Jin Suh. (2005) Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus. Journal of Korean Medical Science 20:5, 821
     

537. 537

     Samuel H. Sigal, Aftab Ala, Katya Ivanov, Sabera Hossain, Carol Bodian, Thomas D. Schiano, Albert D. Min, Henry C. Bodenheimer, Swan N. Thung. (2005) Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy. Liver Transplantation 11:1, 82-88
     

538. 538

     Ronald J Trent. Infectious Diseases. In: Molecular Medicine. Elsevier, 2005:193-220.
     

539. 539

     William B. Coleman. 2 Mechanisms of Human Hepatocardnogenesis: An Overview. Elsevier, 2005:153-170.
     

540. 540

     DIEGO VERGANI, GIORGINA MIELI-VERGANI. (2004) Viral hepatitis: virus/host interaction. Journal of Gastroenterology and Hepatology 19:s7, S307-S310
     

541. 541

     Shau-Feng Chang, Shih-Hsuan Chang, Bi-Chen Li, Hans Will, Hans Jürgen Netter. (2004) Characterization of nonconventional hepatitis B viruses lacking the core promoter. Virology 330:2, 437-446
     

542. 542

     Tarik Asselah, Corinne Castelnau, Nathalie Boyer, Marie-Pierre Ripault, Patrick Marcellin. (2004) Traitement de l’hépatite chronique B. Gastroentérologie Clinique et Biologique 28:12, 1215-1227
     

543. 543

     Daniel H. Li, Atsushi Kumanogoh, Thai M. Cao, Jane R. Parnes, John M. Cullen. (2004) Woodchuck interleukin-6 gene: structure, characterization, and biologic activity. Gene 342:1, 157-164
     

544. 544

     Wands , Jack R. , . (2004) Prevention of Hepatocellular Carcinoma. New England Journal of Medicine 351:15, 1567-1570
     Full Text

545. 545

     Kamana Parashar Misra, Atish Mukherji, Vijay Kumar. (2004) The conserved amino-terminal region (amino acids 1–20) of the hepatitis B virus X protein shows a transrepression function. Virus Research 105:2, 157-165
     

546. 546

     (2004) Hepatitis B. New England Journal of Medicine 350:26, 2719-2720
     Free Full Text

547. 547

     Hans Christian Spangenberg, Robert Thimme, Hubert E. Blum. (2004) Tracking cccDNA in chronic HBV infection. Hepatology 39:6, 1736-1738
     

548. 548

     Núñez Marina, García-Samaniego Javier, Soriano Vicente. (2004) Avances en el diagnóstico y tratamiento de la infección por el virus de la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 22:9, 539-549
     

Letters